<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:blogger='http://schemas.google.com/blogger/2008' xmlns:georss='http://www.georss.org/georss' xmlns:gd="http://schemas.google.com/g/2005" xmlns:thr='http://purl.org/syndication/thread/1.0'><id>tag:blogger.com,1999:blog-4184396470845122639</id><updated>2024-10-04T21:22:42.389-05:00</updated><category term="Latest news from the liposome industry"/><category term="Liposomes"/><category term="Clodronate liposomes"/><category term="Clodronate"/><category term="Clodrosome"/><category term="Macrophage depletion"/><category term="Liposome"/><category term="Antibody conjugation"/><category term="immunoliposomes"/><category term="antibody"/><category term="Educational videos"/><category term="Scientific news"/><category term="Fluorescent liposomes"/><category term="Liposome conferences"/><category term="Liposome protocols"/><category term="cancer"/><category term="immunosome"/><category term="peptide"/><category term="protein"/><category term="size"/><category term="targeting"/><category term="tumor"/><category term="Doxorubicin liposomes"/><category term="EDC"/><category term="Fluoroliposome"/><category term="Lipid movement in liposome bilayer"/><category term="N-terminus"/><category term="carboxylic acid chemistry"/><category term="fusion assay"/><category term="lamellarity"/><category term="sulfo-NHS"/><category term="MSDS"/><category term="NBD/Rhodamine assay"/><category term="drug delivery"/><category term="immunodox"/><category term="liposome. liposomes"/><category term="mannosylated liposomes"/><category term="nanotechnology"/><category term="unilamellar"/><category term="(Fab)2&#39;"/><category term="100 nm"/><category term="ANTS/DPX"/><category term="Antibody digestion"/><category term="Azide"/><category term="C-terminus"/><category term="Click chemistry"/><category term="DBCO"/><category term="Doxil"/><category term="Fab"/><category term="Fab&#39;"/><category term="Ficin"/><category term="Intellectual property"/><category term="Lipodox"/><category term="Liposome size measurement"/><category term="Miscellaneous"/><category term="Myocet"/><category term="NHS activated lipid"/><category term="Number of lipid molecules per liposome"/><category term="Papain"/><category term="Pepsin"/><category term="Technology bloggers"/><category term="doxosome"/><category term="fusion peptides"/><category term="fusogens"/><category term="lipid"/><category term="nanomedicine"/><category term="osmolality"/><category term="pH-sensitive"/><category term="presentations"/><category term="triggered release"/><title type='text'>Liposome: Encapsula&#39;s Scientific Blog</title><subtitle type='html'></subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://www.liposomes.org/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default?redirect=false'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><link rel='next' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default?start-index=26&amp;max-results=25&amp;redirect=false'/><author><name>Encapsula NanoSciences</name><uri>http://www.blogger.com/profile/09825531406425065363</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>98</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>25</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-5612724703283835521</id><published>2020-01-24T16:38:00.001-06:00</published><updated>2020-01-24T16:45:35.406-06:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="cancer"/><category scheme="http://www.blogger.com/atom/ns#" term="nanomedicine"/><category scheme="http://www.blogger.com/atom/ns#" term="nanotechnology"/><category scheme="http://www.blogger.com/atom/ns#" term="tumor"/><title type='text'>The entry of nanoparticles into solid tumours </title><content type='html'>A new publication in Nature Materials by a group in the University of Toronto in Canada. This paper certainly challenges&amp;nbsp;&lt;span style=&quot;background-color: white; color: #1c1e21; font-family: &amp;quot;helvetica&amp;quot; , &amp;quot;arial&amp;quot; , sans-serif; font-size: 14px;&quot;&gt;the Enhanced Permeability and Retention Effect (EPR), a four-decade-old dogma in Nanomedicine.&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;background-color: white; color: #1c1e21; font-family: &amp;quot;helvetica&amp;quot; , &amp;quot;arial&amp;quot; , sans-serif; font-size: 14px;&quot;&gt;&lt;br /&gt;&lt;/span&gt;
&lt;a href=&quot;https://www.nature.com/articles/s41563-019-0566-2&quot;&gt;https://www.nature.com/articles/s41563-019-0566-2&lt;/a&gt;&lt;br /&gt;
&lt;span style=&quot;background-color: white; color: #1c1e21; font-family: &amp;quot;helvetica&amp;quot; , &amp;quot;arial&amp;quot; , sans-serif; font-size: 14px;&quot;&gt;&lt;br /&gt;&lt;/span&gt;
&lt;span style=&quot;background-color: white; color: #1c1e21; font-family: &amp;quot;helvetica&amp;quot; , &amp;quot;arial&amp;quot; , sans-serif; font-size: 14px;&quot;&gt;&lt;br /&gt;&lt;/span&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/5612724703283835521'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/5612724703283835521'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2020/01/the-entry-of-nanoparticles-into-solid.html' title='The entry of nanoparticles into solid tumours '/><author><name>Encapsula NanoSciences</name><uri>http://www.blogger.com/profile/09825531406425065363</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-1785695554982836672</id><published>2018-02-01T11:43:00.000-06:00</published><updated>2018-02-01T11:45:18.121-06:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="antibody"/><category scheme="http://www.blogger.com/atom/ns#" term="Antibody conjugation"/><category scheme="http://www.blogger.com/atom/ns#" term="Azide"/><category scheme="http://www.blogger.com/atom/ns#" term="Click chemistry"/><category scheme="http://www.blogger.com/atom/ns#" term="DBCO"/><category scheme="http://www.blogger.com/atom/ns#" term="Doxorubicin liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="immunodox"/><category scheme="http://www.blogger.com/atom/ns#" term="immunoliposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="immunosome"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposomes"/><title type='text'>DBCO or Azide reactive liposomes (Click chemistry) </title><content type='html'>&lt;div style=&quot;background-color: white; box-sizing: border-box; color: #262626; font-family: &amp;quot;Helvetica Neue&amp;quot;, Helvetica, Arial, sans-serif; font-size: 13px; margin-bottom: 20px; text-align: justify;&quot;&gt;
&lt;span style=&quot;box-sizing: border-box;&quot;&gt;For the past 50 years various types of chemistries have been used for conjugation of molecules such as antibodies, peptides, proteins or other reactive ligands to the surface of liposomes. In general the conjugation can be achieved through the N-terminus, the C-terminus or the available sulfur (Fab’ fraction or thiolated antibodies). Not all chemistries have the same yield and efficiency of conjugation and often reproducing biocompatible batches can be a challenge.&lt;/span&gt;&lt;/div&gt;
&lt;div style=&quot;background-color: white; box-sizing: border-box; color: #262626; font-family: &amp;quot;Helvetica Neue&amp;quot;, Helvetica, Arial, sans-serif; font-size: 13px; margin-bottom: 20px; text-align: justify;&quot;&gt;
&lt;span style=&quot;box-sizing: border-box;&quot;&gt;Copper-free click chemistry is a fairly new chemistry that has been commercialized during the past few years. More and more click chemistry based reagents are becoming available commercially which makes the formulation development much easier for scientists. The great advantage of this chemistry is biocompatibility since no cytotoxic copper catalyst is required.&lt;/span&gt;&lt;/div&gt;
&lt;div style=&quot;background-color: white; box-sizing: border-box; color: #262626; font-family: &amp;quot;Helvetica Neue&amp;quot;, Helvetica, Arial, sans-serif; font-size: 13px; margin-bottom: 20px; text-align: justify;&quot;&gt;
&lt;span style=&quot;box-sizing: border-box;&quot;&gt;By far, click chemistry is the most efficient and easiest conjugation chemistry available for coupling of antibodies and other reactive ligands to the surface of the liposomes. The conjugation chemistry is based on the reaction of the dibenzocyclooctyne (DBCO) reagent with an azide linker to form a stable triazole. DBCO moiety can be on the antibody and azide moiety can be on liposomes and vice versa.&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;separator&quot; style=&quot;clear: both; text-align: center;&quot;&gt;
&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhZX2kwBL4bkF-OZL2rdo85_mJWBTh5UoBvoY9hdmw7wmgM4b4mOh_UrYFQvE8nd-yGZ-cHUJZfn6WZkvBAPZgCg3WfXxuUQ6NpdMo5RSlHMDvkXfFn_V0pDrZ7Xb78o1MA57dKViZ30HM/s1600/Click+chemistry-+Reaction+of+azide+liposomes+with+DBCO+tagged+antibody.jpg&quot; imageanchor=&quot;1&quot; style=&quot;margin-left: 1em; margin-right: 1em;&quot;&gt;&lt;img border=&quot;0&quot; data-original-height=&quot;1596&quot; data-original-width=&quot;1600&quot; height=&quot;319&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhZX2kwBL4bkF-OZL2rdo85_mJWBTh5UoBvoY9hdmw7wmgM4b4mOh_UrYFQvE8nd-yGZ-cHUJZfn6WZkvBAPZgCg3WfXxuUQ6NpdMo5RSlHMDvkXfFn_V0pDrZ7Xb78o1MA57dKViZ30HM/s320/Click+chemistry-+Reaction+of+azide+liposomes+with+DBCO+tagged+antibody.jpg&quot; width=&quot;320&quot; /&gt;&lt;/a&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;div class=&quot;separator&quot; style=&quot;clear: both; text-align: center;&quot;&gt;
&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi9FS8APSQnYGl4V9vi6jhwsrF17k0MHz9n2R4NyhJtbSINHyYe44RRIW37ABMoHSnykFJKXtRsNu1GNGks3jG3pykg1ksL_5Ikz_jROLdmNrRMQ-Y_f6p6S1I9B9jLz54tjBrO6VvG5RQ/s1600/Click+chemistry-+Reaction+of+DBCO+liposomes+with+azide+tagged+antibody.jpg&quot; imageanchor=&quot;1&quot; style=&quot;margin-left: 1em; margin-right: 1em;&quot;&gt;&lt;img border=&quot;0&quot; data-original-height=&quot;1596&quot; data-original-width=&quot;1600&quot; height=&quot;319&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi9FS8APSQnYGl4V9vi6jhwsrF17k0MHz9n2R4NyhJtbSINHyYe44RRIW37ABMoHSnykFJKXtRsNu1GNGks3jG3pykg1ksL_5Ikz_jROLdmNrRMQ-Y_f6p6S1I9B9jLz54tjBrO6VvG5RQ/s320/Click+chemistry-+Reaction+of+DBCO+liposomes+with+azide+tagged+antibody.jpg&quot; width=&quot;320&quot; /&gt;&lt;/a&gt;&lt;/div&gt;
&lt;div style=&quot;background-color: white; box-sizing: border-box; color: #262626; font-family: &amp;quot;Helvetica Neue&amp;quot;, Helvetica, Arial, sans-serif; font-size: 13px; margin-bottom: 20px; text-align: justify;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div style=&quot;background-color: white; box-sizing: border-box; color: #262626; font-family: &amp;quot;Helvetica Neue&amp;quot;, Helvetica, Arial, sans-serif; font-size: 13px; margin-bottom: 20px; text-align: justify;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/1785695554982836672'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/1785695554982836672'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2018/02/dbco-or-azide-reactive-liposomes-click.html' title='DBCO or Azide reactive liposomes (Click chemistry) '/><author><name>Encapsula NanoSciences</name><uri>http://www.blogger.com/profile/09825531406425065363</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhZX2kwBL4bkF-OZL2rdo85_mJWBTh5UoBvoY9hdmw7wmgM4b4mOh_UrYFQvE8nd-yGZ-cHUJZfn6WZkvBAPZgCg3WfXxuUQ6NpdMo5RSlHMDvkXfFn_V0pDrZ7Xb78o1MA57dKViZ30HM/s72-c/Click+chemistry-+Reaction+of+azide+liposomes+with+DBCO+tagged+antibody.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-335598155313026224</id><published>2015-01-21T12:40:00.003-06:00</published><updated>2015-01-21T12:52:54.814-06:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="(Fab)2&#39;"/><category scheme="http://www.blogger.com/atom/ns#" term="antibody"/><category scheme="http://www.blogger.com/atom/ns#" term="Antibody conjugation"/><category scheme="http://www.blogger.com/atom/ns#" term="Antibody digestion"/><category scheme="http://www.blogger.com/atom/ns#" term="C-terminus"/><category scheme="http://www.blogger.com/atom/ns#" term="Fab"/><category scheme="http://www.blogger.com/atom/ns#" term="Fab&#39;"/><category scheme="http://www.blogger.com/atom/ns#" term="Ficin"/><category scheme="http://www.blogger.com/atom/ns#" term="immunoliposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="immunosome"/><category scheme="http://www.blogger.com/atom/ns#" term="liposome. liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="N-terminus"/><category scheme="http://www.blogger.com/atom/ns#" term="Papain"/><category scheme="http://www.blogger.com/atom/ns#" term="Pepsin"/><title type='text'>Antibody structure and Fragments</title><content type='html'>This is an educational video that shows the antibody structure and fragments that are made during digestion with various enzymes such as Pepsin, Papain and Ficin. If you need to conjugated your antibody through available free sulfur to the reactive group on the surface of the liposomes such as Maleimide, PDP, MCC or MPB then the antibody has to be digested and the disulfide bridge should be broken by using reducing agents such as DTT.&lt;br /&gt;
&lt;br /&gt;
The video also shows various methods for making antibody fragments that are suitable for conjugation through N-terminus or C-terminus.&lt;br /&gt;
&lt;br /&gt;
&amp;nbsp;


&lt;iframe allowfullscreen=&quot;&quot; frameborder=&quot;0&quot; height=&quot;315&quot; src=&quot;//www.youtube.com/embed/wXs27cxxwkQ&quot; width=&quot;560&quot;&gt;&lt;/iframe&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/335598155313026224'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/335598155313026224'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2015/01/antibody-structure-and-fragments.html' title='Antibody structure and Fragments'/><author><name>Encapsula NanoSciences</name><uri>http://www.blogger.com/profile/09825531406425065363</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-4630238688414752009</id><published>2015-01-20T12:51:00.002-06:00</published><updated>2015-01-20T12:53:38.511-06:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="antibody"/><category scheme="http://www.blogger.com/atom/ns#" term="Antibody conjugation"/><category scheme="http://www.blogger.com/atom/ns#" term="cancer"/><category scheme="http://www.blogger.com/atom/ns#" term="carboxylic acid chemistry"/><category scheme="http://www.blogger.com/atom/ns#" term="drug delivery"/><category scheme="http://www.blogger.com/atom/ns#" term="EDC"/><category scheme="http://www.blogger.com/atom/ns#" term="lamellarity"/><category scheme="http://www.blogger.com/atom/ns#" term="peptide"/><category scheme="http://www.blogger.com/atom/ns#" term="protein"/><category scheme="http://www.blogger.com/atom/ns#" term="size"/><category scheme="http://www.blogger.com/atom/ns#" term="sulfo-NHS"/><category scheme="http://www.blogger.com/atom/ns#" term="targeting"/><category scheme="http://www.blogger.com/atom/ns#" term="tumor"/><category scheme="http://www.blogger.com/atom/ns#" term="unilamellar"/><title type='text'>Immunoliposomes: How to conjugate antibodies, proteins and peptides to the surface of the liposomes</title><content type='html'>&lt;iframe width=&quot;560&quot; height=&quot;315&quot; src=&quot;//www.youtube.com/embed/cbYAH6JGZpA&quot; frameborder=&quot;0&quot; allowfullscreen&gt;&lt;/iframe&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/4630238688414752009'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/4630238688414752009'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2015/01/immunoliposomes-how-to-conjugate.html' title='Immunoliposomes: How to conjugate antibodies, proteins and peptides to the surface of the liposomes'/><author><name>Encapsula NanoSciences</name><uri>http://www.blogger.com/profile/09825531406425065363</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-5995600937225605195</id><published>2015-01-19T16:05:00.000-06:00</published><updated>2015-01-21T12:53:33.787-06:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="immunosome"/><category scheme="http://www.blogger.com/atom/ns#" term="lamellarity"/><category scheme="http://www.blogger.com/atom/ns#" term="liposome. liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="size"/><category scheme="http://www.blogger.com/atom/ns#" term="unilamellar"/><title type='text'>Liposome size calculation</title><content type='html'>The animation below only applies to unilamellar liposomes.&lt;br /&gt;
&lt;br /&gt;
&amp;nbsp; 


&lt;iframe allowfullscreen=&quot;&quot; frameborder=&quot;0&quot; height=&quot;315&quot; src=&quot;//www.youtube.com/embed/xAiSPIT4L6o&quot; width=&quot;560&quot;&gt;&lt;/iframe&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/5995600937225605195'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/5995600937225605195'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2015/01/liposome-size-calculation.html' title='Liposome size calculation'/><author><name>Encapsula NanoSciences</name><uri>http://www.blogger.com/profile/09825531406425065363</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-8741086214635116828</id><published>2014-09-17T02:28:00.000-05:00</published><updated>2014-09-17T02:29:38.313-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="antibody"/><category scheme="http://www.blogger.com/atom/ns#" term="Antibody conjugation"/><category scheme="http://www.blogger.com/atom/ns#" term="Doxorubicin liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="doxosome"/><category scheme="http://www.blogger.com/atom/ns#" term="drug delivery"/><category scheme="http://www.blogger.com/atom/ns#" term="immunodox"/><category scheme="http://www.blogger.com/atom/ns#" term="immunoliposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="immunosome"/><category scheme="http://www.blogger.com/atom/ns#" term="lipid"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposome"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="nanotechnology"/><category scheme="http://www.blogger.com/atom/ns#" term="peptide"/><category scheme="http://www.blogger.com/atom/ns#" term="protein"/><category scheme="http://www.blogger.com/atom/ns#" term="targeting"/><title type='text'>Doxorubicin liposomes</title><content type='html'>&lt;iframe width=&quot;560&quot; height=&quot;315&quot; src=&quot;//www.youtube.com/embed/27nxR8M344Q&quot; frameborder=&quot;0&quot; allowfullscreen&gt;&lt;/iframe&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/8741086214635116828'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/8741086214635116828'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2014/09/doxorubicin-liposomes.html' title='Doxorubicin liposomes'/><author><name>Encapsula NanoSciences</name><uri>http://www.blogger.com/profile/09825531406425065363</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-376090756278653624</id><published>2014-08-22T21:08:00.001-05:00</published><updated>2014-08-22T21:12:03.537-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="antibody"/><category scheme="http://www.blogger.com/atom/ns#" term="Antibody conjugation"/><category scheme="http://www.blogger.com/atom/ns#" term="cancer"/><category scheme="http://www.blogger.com/atom/ns#" term="carboxylic acid chemistry"/><category scheme="http://www.blogger.com/atom/ns#" term="EDC"/><category scheme="http://www.blogger.com/atom/ns#" term="immunoliposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposome"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposome protocols"/><category scheme="http://www.blogger.com/atom/ns#" term="N-terminus"/><category scheme="http://www.blogger.com/atom/ns#" term="NHS activated lipid"/><category scheme="http://www.blogger.com/atom/ns#" term="peptide"/><category scheme="http://www.blogger.com/atom/ns#" term="protein"/><category scheme="http://www.blogger.com/atom/ns#" term="sulfo-NHS"/><category scheme="http://www.blogger.com/atom/ns#" term="targeting"/><category scheme="http://www.blogger.com/atom/ns#" term="tumor"/><title type='text'>Antibody Liposome Conjugation: Using NHS activated lipid</title><content type='html'>&lt;iframe width=&quot;560&quot; height=&quot;315&quot; src=&quot;//www.youtube.com/embed/UGB45syFCkE&quot; frameborder=&quot;0&quot; allowfullscreen&gt;&lt;/iframe&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/376090756278653624'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/376090756278653624'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2014/08/antibody-liposome-conjugation-using-nhs.html' title='Antibody Liposome Conjugation: Using NHS activated lipid'/><author><name>Encapsula NanoSciences</name><uri>http://www.blogger.com/profile/09825531406425065363</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-2890859621778408051</id><published>2014-08-22T21:04:00.000-05:00</published><updated>2014-08-22T21:11:20.906-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="antibody"/><category scheme="http://www.blogger.com/atom/ns#" term="Antibody conjugation"/><category scheme="http://www.blogger.com/atom/ns#" term="cancer"/><category scheme="http://www.blogger.com/atom/ns#" term="carboxylic acid chemistry"/><category scheme="http://www.blogger.com/atom/ns#" term="EDC"/><category scheme="http://www.blogger.com/atom/ns#" term="immunoliposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposome"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposome protocols"/><category scheme="http://www.blogger.com/atom/ns#" term="N-terminus"/><category scheme="http://www.blogger.com/atom/ns#" term="peptide"/><category scheme="http://www.blogger.com/atom/ns#" term="protein"/><category scheme="http://www.blogger.com/atom/ns#" term="sulfo-NHS"/><category scheme="http://www.blogger.com/atom/ns#" term="targeting"/><category scheme="http://www.blogger.com/atom/ns#" term="tumor"/><title type='text'>Antibody Liposome Conjugation: Carboxylic Acid Chemistry</title><content type='html'>&lt;iframe width=&quot;560&quot; height=&quot;315&quot; src=&quot;//www.youtube.com/embed/wHOZwJ4Gu9s&quot; frameborder=&quot;0&quot; allowfullscreen&gt;&lt;/iframe&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/2890859621778408051'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/2890859621778408051'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2014/08/antibody-liposome-conjugation.html' title='Antibody Liposome Conjugation: Carboxylic Acid Chemistry'/><author><name>Encapsula NanoSciences</name><uri>http://www.blogger.com/profile/09825531406425065363</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-1869023765852951911</id><published>2013-12-08T22:02:00.001-06:00</published><updated>2013-12-08T22:02:33.826-06:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Antibody conjugation"/><category scheme="http://www.blogger.com/atom/ns#" term="immunoliposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposome"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposomes"/><title type='text'>Antibody-Liposome Association Using Avidin-Biotin Binding</title><content type='html'>&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhl7iGpFrJtgYas9oRri_qJaJYVTiDr1CDeCNj9fjczy09dAfYwCilHOUvse2vQFIlMWPqikAeb2NkFDRPhrXHsN0LNzvb-5kcAcKCU7-rGXXKLxR8jhh_IvxlH5JnxvN1CxU8XHqtZc6M/s1600/Biotinylated-liposome.jpg&quot; imageanchor=&quot;1&quot; &gt;&lt;img border=&quot;0&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhl7iGpFrJtgYas9oRri_qJaJYVTiDr1CDeCNj9fjczy09dAfYwCilHOUvse2vQFIlMWPqikAeb2NkFDRPhrXHsN0LNzvb-5kcAcKCU7-rGXXKLxR8jhh_IvxlH5JnxvN1CxU8XHqtZc6M/s400/Biotinylated-liposome.jpg&quot; /&gt;&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/1869023765852951911'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/1869023765852951911'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2013/12/antibody-liposome-association-using.html' title='Antibody-Liposome Association Using Avidin-Biotin Binding'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhl7iGpFrJtgYas9oRri_qJaJYVTiDr1CDeCNj9fjczy09dAfYwCilHOUvse2vQFIlMWPqikAeb2NkFDRPhrXHsN0LNzvb-5kcAcKCU7-rGXXKLxR8jhh_IvxlH5JnxvN1CxU8XHqtZc6M/s72-c/Biotinylated-liposome.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-1716840843737645763</id><published>2013-12-08T21:00:00.001-06:00</published><updated>2013-12-08T21:00:15.137-06:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Antibody conjugation"/><category scheme="http://www.blogger.com/atom/ns#" term="immunoliposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposome"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposomes"/><title type='text'>Separation of free antibodies from immunoliposomes-Dialysis method</title><content type='html'>&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiZdGfTuMbzCuTl3XM95RjC69YqTq0yTen1oxTI3V9JfRMzQL2O_nSKb0IOuxhfFe9g3Yfveu5GmohSwqrGjrjC_BacYNUzKgUXJm2tXgC1GitQHft7KYFa01tlLkKlunmd4SE2A2eXmD4/s1600/Separation+of+free+antibodies+from+immunoliposomes.jpg&quot; imageanchor=&quot;1&quot; &gt;&lt;img border=&quot;0&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiZdGfTuMbzCuTl3XM95RjC69YqTq0yTen1oxTI3V9JfRMzQL2O_nSKb0IOuxhfFe9g3Yfveu5GmohSwqrGjrjC_BacYNUzKgUXJm2tXgC1GitQHft7KYFa01tlLkKlunmd4SE2A2eXmD4/s400/Separation+of+free+antibodies+from+immunoliposomes.jpg&quot; /&gt;&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/1716840843737645763'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/1716840843737645763'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2013/12/separation-of-free-antibodies-from.html' title='Separation of free antibodies from immunoliposomes-Dialysis method'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiZdGfTuMbzCuTl3XM95RjC69YqTq0yTen1oxTI3V9JfRMzQL2O_nSKb0IOuxhfFe9g3Yfveu5GmohSwqrGjrjC_BacYNUzKgUXJm2tXgC1GitQHft7KYFa01tlLkKlunmd4SE2A2eXmD4/s72-c/Separation+of+free+antibodies+from+immunoliposomes.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-2532703838286497956</id><published>2013-12-08T19:30:00.001-06:00</published><updated>2013-12-08T19:32:16.716-06:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Antibody conjugation"/><category scheme="http://www.blogger.com/atom/ns#" term="immunoliposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposome"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposome conferences"/><title type='text'>Surface Modified Liposomes- Different methods for conjugation of antibodies, proteins and peptides to the surface of the liposomes</title><content type='html'>&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiW6TbvFzpWeypXHOC-m41bRBt6bgeVLAGVMyRnpup8opaQ-dnHi4fHljDcL3gqC3xLY3NbR185ATuN7X_k4k3j08uhQWSfgSTneblMwtjQmI3JIkgbCJwNYMi6lXuzy93bU0Y4Zv7vshc/s1600/Surface+modified+liposomes_Immunoliposomes_Encapsula+NanoSciences.jpg&quot; imageanchor=&quot;1&quot; &gt;&lt;img border=&quot;0&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiW6TbvFzpWeypXHOC-m41bRBt6bgeVLAGVMyRnpup8opaQ-dnHi4fHljDcL3gqC3xLY3NbR185ATuN7X_k4k3j08uhQWSfgSTneblMwtjQmI3JIkgbCJwNYMi6lXuzy93bU0Y4Zv7vshc/s400/Surface+modified+liposomes_Immunoliposomes_Encapsula+NanoSciences.jpg&quot; /&gt;&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/2532703838286497956'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/2532703838286497956'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2013/12/surface-modified-liposomes-different.html' title='Surface Modified Liposomes- Different methods for conjugation of antibodies, proteins and peptides to the surface of the liposomes'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiW6TbvFzpWeypXHOC-m41bRBt6bgeVLAGVMyRnpup8opaQ-dnHi4fHljDcL3gqC3xLY3NbR185ATuN7X_k4k3j08uhQWSfgSTneblMwtjQmI3JIkgbCJwNYMi6lXuzy93bU0Y4Zv7vshc/s72-c/Surface+modified+liposomes_Immunoliposomes_Encapsula+NanoSciences.jpg" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-5372763476056106774</id><published>2013-12-03T21:44:00.003-06:00</published><updated>2013-12-03T21:46:34.284-06:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodrosome"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposome"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Macrophage depletion"/><category scheme="http://www.blogger.com/atom/ns#" term="mannosylated liposomes"/><title type='text'>How to inject Clodronate liposomes- Part 1</title><content type='html'>&lt;iframe allowfullscreen=&quot;&quot; frameborder=&quot;0&quot; height=&quot;315&quot; src=&quot;//www.youtube.com/embed/c53zysfvF50&quot; width=&quot;560&quot;&gt;&lt;/iframe&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/5372763476056106774'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/5372763476056106774'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2013/12/how-to-inject-clodronate-liposomes-part.html' title='How to inject Clodronate liposomes- Part 1'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-7459530295097415990</id><published>2013-01-04T16:41:00.001-06:00</published><updated>2013-01-04T16:41:30.562-06:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Latest news from the liposome industry"/><title type='text'>Celator commences third phase of leukemia study CPX-351 (Cytarabine:Daunorubicin) liposome)</title><content type='html'>&lt;br /&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
Celator Pharmaceuticals has commenced patient enrollment in the phase-III study of CPX-351 in untreated high-risk acute myeloid leukemia (AML).&lt;/div&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
&lt;/div&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
The open-label trial is designed to assess CPX-351 (cytarabine:daunorubicin) liposome injection compared to cytarabine and daunorubicin therapy (7+3) as first-line therapy in high risk (secondary) AML patients 60-75 year old.&lt;/div&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
Celator chief medical officer Arthur Louie said, &quot;Clinical studies completed to date suggest that CPX-351 may provide an opportunity to improve outcomes in AML, particularly for high-risk patients whose prognosis on standard therapy is poor.&quot;&lt;/div&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
Patients who have pathological diagnosis of AML based on WHO criteria, with confirmation of therapy-related AML, AML with a history of myelodysplasia (MDS), AML with a history of chronic myelomonocytic leukemia, De novo AML with karyotypic abnormalities characteristic of MDS will participate in the study.&lt;/div&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
Subjects will be randomized with either CPX-351 (100u/m2; days one, three, and five by 90 minute infusion) or 7+3 (cytarabine 100mg/m2/day by continuous infusion for seven days and daunorubicin 60mg/m2 on days one, two, and three) in 1:1 ratio and will be assessed for clinical adverse events in addition to laboratory evaluations.&lt;/div&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
Overall survival is the primary efficacy endpoint of the multicenter study scheduled to be conducted in the US and Canada.&lt;/div&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
Celator chief executive officer Scott Jackson said, &quot;The initiation of this study is an important milestone for CPX-351 and for Celator. We hope the data it provides will allow us to seek regulatory approval for CPX-351 and, ultimately, make an important and much-needed treatment option available to patients with AML.&quot;&lt;/div&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
The company is conducting the study in collaboration with The Leukemia &amp;amp; Lymphoma Society (LLS), which supported the CPX-351 development through its Therapy Acceleration Program.&lt;/div&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
Original articles:&lt;/div&gt;
&lt;div style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 13px;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;span style=&quot;color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: x-small;&quot;&gt;&lt;a href=&quot;http://clinicaltrials.pharmaceutical-business-review.com/news/celator-commences-third-phase-of-leukemia-study-cpx-351-271212&quot;&gt;http://clinicaltrials.pharmaceutical-business-review.com/news/celator-commences-third-phase-of-leukemia-study-cpx-351-271212&lt;/a&gt;&lt;/span&gt;&lt;br /&gt;
</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/7459530295097415990'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/7459530295097415990'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2013/01/celator-commences-third-phase-of.html' title='Celator commences third phase of leukemia study CPX-351 (Cytarabine:Daunorubicin) liposome)'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-2865769091467204992</id><published>2012-08-31T08:10:00.000-05:00</published><updated>2012-08-31T08:11:15.464-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodrosome"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposome"/><category scheme="http://www.blogger.com/atom/ns#" term="Macrophage depletion"/><title type='text'>Intrarectal Administration of Clodronate Liposomes</title><content type='html'>&lt;br /&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Currently, a single paper cited intrarectal administration of clodronate liposomes [1]. Few details of the the instillation method were provided and it is unclear as to whether a polycarbonate tip on an automatic pipettor or a glass-capillary type micropipette was used for the instillation of the liposome suspension. The key questions relate to how long the suspension was retained in the colon and how far into the colon the suspension penetrated although the authors observe that macrophage depletion was limited to the descending colon. The authors do not report fasting the animals or eliminating fiber from the animal diet prior to dosing the clodronate liposomes as has been incorporated into other protocols for colitis [2]. Likewise, the effectiveness of the instilled liposome suspension would seem to be affected by the colon content at the time of dosing.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
The appropriate volumes for enemas is reported to be 0.2 ml for mice and 1 ml for rats [2] although several papers use 0.1 ml doses in mice and as much as 3 ml in rats. We have not identified standard protocols for intrarectal injections in rodents, but many report holding the rodents in a vertical, head-down position for a minute or so post-intrarectal instillation. This would appear to be a reasonable addition to the method that should increase the efficacy of intrarectal delivery.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Many also utilize rubber or plastic tubing for delivering the liquids 2 cm or more beyond the rectum into the descending colon, or more specifically, an intracolonic instillation. Since the rectal tissue plays little or no role in the disease process, ensuring that the clodronate liposome suspension has maximal access to the colon may enhance and/or extend the depletion period. A study utilizing fluorescently- and/or visibly- (&lt;a href=&quot;http://www.clodrosome.com/products/standard-clodrosome-reagents/fluoroliposome/&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: none; vertical-align: baseline;&quot; target=&quot;_blank&quot; title=&quot;Fluoroliposome&quot;&gt;DiI&amp;nbsp;&lt;/a&gt;incorporation accomplishes both) labelled liposomes could assist in the evaluation of the retention of the intrarectally-delivered liposomes as well as their distribution within the colon.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Colonic macrophages have been shown to demonstrate decreased phagocytic activity due to the ingestion of dextran sodium sulfate (DSS) [3, 4, 5]. The majority of the data in this paper was collected in animals which were dosed with clodronate liposomes on days -1, +1, +3 and +5; the animals were given water containing DSS beginning on day 0. This could mean that treatment with clodronate liposomes post-oral administration of DSS to mice may result in ineffective depletion due to limited uptake of clodronate liposomes by colonic macrophages which are non-phagocytic due to blockade by DSS, thus the surprisingly rapid repopulation (50% replenished by day 7) of macrophages even after 4 intrarectal treatments with clodronate liposomes. If DSS is dosed to the animals prior to any clodronate liposome treatment, would any&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;&amp;nbsp;depletion be observed? We believe that this is an important factor to consider.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Another contrary interpretation of the data in the Qualls,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&amp;nbsp;&lt;/em&gt;paper is that macrophage uptake of DSS may limit DSS-induced inflammation, therefore macrophage depletion may result in the colon tissues being exposed to higher levels of DSS.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Qualls,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&amp;nbsp;&lt;/em&gt;chose not to include empty liposome control groups in their studies due to the fact that the control liposomes induced “a partial reduction in the percentage of&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;&amp;nbsp;in the colon and could affect the physiology of the remaining colonic&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;&amp;nbsp;(data not shown…” We would argue that this is precisely the rationale for including empty liposome controls and that any results should be compared to those obtained with empty liposome controls. These control results may very well have elucidated some of the potential effects of macrophages in the disease. For example, does a reduction in the phagocytic capacity of macrophages (due to liposome uptake without associated toxicity ) and in the absence of macrophage destruction have any effect on the disease?&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;&amp;nbsp;blockade by control liposomes could reduce the uptake of DSS by the resident MΦ; this may reduce the initial inflammatory response since&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;&amp;nbsp;would not be able to phagocytose DSS or worsen the disease because uptake of DSS by resident&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;&amp;nbsp;lessens the DSS effect on colonic tissue. Any reduction in the number of&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;&amp;nbsp;in the colon or changes in&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;&amp;nbsp;morphology induced by control (empty) liposomes should have been a transient reaction since liposomes are not toxic to&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;, but they can inhibit&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;&amp;nbsp;phagocytosis for several hours.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
It is common to observe an increase in neutrophil infiltration into the pulmonary space post-clodronate, but not control, liposome treatment. Perhaps neutrophil infiltration as a result of clodronate liposome treatment is a factor in this model as well, but no clodronate-liposome treated animals in the absence of DSS-induced colitis were evaluated for neutrophil infiltration.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
And, finally, a primary function of the colon is in providing a highly effective barrier around the colon. Therefore, it is possible that this barrier is impermeable to free clodronate and that clodronate released from liposomes or dead/dying macrophages could temporarily accumulate locally attaining concentrations which could effect surrounding cells (see&amp;nbsp;&lt;a href=&quot;http://www.clodrosome.com/routes-of-administration/intrapulmonary/&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: none; vertical-align: baseline;&quot; target=&quot;_blank&quot; title=&quot;Intrapulmonary&quot;&gt;Intrapulmonary Administration&amp;nbsp;&lt;/a&gt;for detailed discussion). While clodronate sequestration seems most unlikely inside the colon, it remains a pertinent control since intracolonic clodronate administration has not been previously evaluated to our knowledge.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
This paper illustrates the necessity of considering the effects of control and clodronate liposomes on the chosen model. Given that the model employed a particulate agent (DSS) which is phagocytosed by&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;, detailed analysis of the effects of&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;&amp;nbsp;blockade by both DSS, clodronate liposomes and control liposomes must be performed. Since each of these particles will likely evoke&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;&amp;nbsp;blockade, any observed results may simply be due to which particle reached the&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;&amp;nbsp;first.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Wanatabe,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&amp;nbsp;&lt;/em&gt;utilized poly-lactic acid&amp;nbsp;µspheres containing clodronate, dosed intrarectally, to deplete macrophages in an IL-10 deficient mouse model of colitis, therefore the only particle type affecting the&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;&amp;nbsp;was the clodronate µspheres [7]. Unfortunately, they did not assess the effects of control µspheres (without clodronate), but they did observe increased disease activity when the colonic&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;&amp;nbsp;were depleted. Their study was much less rigorous than the Qualls,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&amp;nbsp;&lt;/em&gt;study as they did not pursue the effects of neutrophil infiltration nor evaluate cytokine and chemokine production. However, their study results do suggest that the use of a particulate material in inducing the collitis, as Qualls,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&amp;nbsp;&lt;/em&gt;did, does not change the conclusion that colonic macrophages play a pivotal role in ameliorating acute colitis in these animal models.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
More recently, Qualls&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&amp;nbsp;&lt;/em&gt;reported that depletion of dendritic cells (&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Dendritic Cell&quot;&gt;DC&lt;/acronym&gt;) alone in CD11c-DTR mice suppressed DSS-induced colitis, but without the concomitant increase in CXCL1, neutrophil influx and MPO activity [8]. We believe that this result further presses the question of the role of clodronate liposomes (or clodronate liposome&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;&amp;nbsp;depletion) in neutrophil influx and activation. An initial, single dose of intrarectal clodronate liposomes for depleting resident MΦ/DC along with multiple intravenous doses of clodronate liposomes could perhaps accomplish colonic MΦ/DC depletion and prevent subsequent repopulation (by depleting circulating monocytes) allowing for colonic recovery from any potential effects of clodronate liposome&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;&amp;nbsp;depletion, such as neutrophil influx, should it occur. Induction of DSS-mediated colitis post-recovery would allow distinction of possible neutrophil influx and activation as a result of clodronate liposome depletion from the neutrophil effects due to the absence of colonic&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Again, we emphasize that although the goal of clodronate liposome-mediated macrophage depletion is usually to generate animals which are normal in every other way except that they are devoid of macrophages, there can be effects due to&lt;/div&gt;
&lt;ol style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; list-style-image: initial; list-style-position: initial; margin: 0px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Liposome administration…control groups treated with empty liposomes are necessary.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Clodronate administration…control groups treated with unencapsulated (free) clodronate are necessary.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Clodronate liposome administration…macrophages are not killed for several hours post-treatment and may not behave as untreated macrophages in the interim.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Macrophage death…even relatively “silent” apoptotic cell death will solicit other macrophages, immature monocytes or other cells (i.e. neutrophils) to clear cellular debris and these cells may “report” extensive cell death in order to recruit replacement mononuclear cells.&lt;/li&gt;
&lt;/ol&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Therefore, experiments elucidating the&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;effects of the process of macrophage depletion&amp;nbsp;&lt;/em&gt;may need to be considered and incorporated into the study.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
The authors further reported an increase in IL-6 as a result of&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Dendritic Cell&quot;&gt;DC&lt;/acronym&gt;&amp;nbsp;depletion and suggested that IL-6 may be the key to the increased severity in colitis after&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Dendritic Cell&quot;&gt;DC&lt;/acronym&gt;&amp;nbsp;depletion. While these authors stated that IL-6 is reported to inhibit neutrophil infiltration, at least one of their cited references exclusively discusses the proinflammatory effects of IL-6 on neutrophils and other cells [9]. (Two of the other references appear to focus on the anti-inflammatory effects of IL-6 in exercise-induced inflammation.) IL-6 or its mRNA levels were not evaluated in the earlier study in which clodronate liposomes were used to deplete MΦ/DC, but the authors reported in this 2009 paper that they observed an increase in IL-6 production when both&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Macrophage&quot;&gt;MΦ&lt;/acronym&gt;&amp;nbsp;and&amp;nbsp;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Dendritic Cell&quot;&gt;DC&lt;/acronym&gt;&amp;nbsp;were depleted (unpublished data) although the mode of depletion was not specified. While we are not well read in the substantial literature on experimental colitis, we believe that clodronate liposome studies including the controls that we proposed earlier may be helpful in dissecting the contributions of the various inflammatory cells, cytokines and chemokines in this model.&lt;/div&gt;
&lt;hr style=&quot;background-color: white; border-bottom-width: 0px; border-color: rgb(204, 204, 204); border-left-width: 0px; border-right-width: 0px; border-style: solid; clear: both; color: #050505; font-family: Arial; font-size: 14px; height: 0px; line-height: 23px; margin-bottom: 20px;&quot; /&gt;
&lt;h5 style=&quot;background-color: white; border: 0px; color: #373738; font-family: Arial; font-size: 1.5em !important; font-weight: normal; line-height: 1.2em; margin: 15px 0px 2px; outline: 0px; padding: 0px 0px 2px; vertical-align: baseline;&quot;&gt;
References&lt;/h5&gt;
&lt;hr style=&quot;background-color: white; border-bottom-width: 0px; border-color: rgb(204, 204, 204); border-left-width: 0px; border-right-width: 0px; border-style: solid; clear: both; color: #050505; font-family: Arial; font-size: 14px; height: 0px; line-height: 23px; margin-bottom: 20px;&quot; /&gt;
&lt;ol style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; list-style-image: initial; list-style-position: initial; margin: 0px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Qualls JE, Kaplan AM, van Rooijen N, Cohen DA.&amp;nbsp;&lt;a href=&quot;http://www.jleukbio.org/content/80/4/802&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: none; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Suppression of experimental colitis by intestinal mononuclear phagocytes.&amp;nbsp;&lt;/a&gt;J Leukoc Biol. 2006 Oct 1;80(4):802–15.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Fretland DJ, Widomski DL, Anglin CP, Walsh RE, Levin S, Gasiecki AF, et al.&amp;nbsp;&lt;a href=&quot;http://www.springerlink.com/content/glrh1m0174026002/abstract/&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: none; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Mucosal protective activity of prostaglandin analogs in rodent colonic inflammation.&amp;nbsp;&lt;/a&gt;Inflammation. 1992;16(6):623–9.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Dieleman, Palmen, Akol, Bloemena, Peña, Meuwissen, et al.&amp;nbsp;&lt;a href=&quot;http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2249.1998.00728.x/abstract&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: none; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines.&amp;nbsp;&lt;/a&gt;Clinical &amp;amp; Experimental Immunology. 1998;114(3):385–91.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R.&amp;nbsp;&lt;a href=&quot;http://ukpmc.ac.uk/abstract/MED/1688816&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: none; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice.&amp;nbsp;&lt;/a&gt;Gastroenterology. 1990 Mar;98(3):694–702.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Ohkusa T, Okayasu I, Tokoi S, Araki A, Ozaki Y.&amp;nbsp;&lt;a href=&quot;http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowAbstractBuch&amp;amp;ArtikelNr=201236&amp;amp;ProduktNr=242180&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: none; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Changes in Bacterial Phagocytosis of Macrophages in Experimental Ulcerative Colitis.&lt;/a&gt;Digestion. 1995;56(2):159–64.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Venkatraman A, Ramakrishna BS, Pulimood AB, Patra S, Murthy S.&amp;nbsp;&lt;a href=&quot;http://informahealthcare.com/doi/abs/10.1080/003655200451171&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: none; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Increased Permeability in Dextran Sulphate Colitis in Rats: Time Course of Development and Effect of Butyrate.&amp;nbsp;&lt;/a&gt;Scandinavian Journal of Gastroenterology. 2000 Oct;35(10):1053–9.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Watanabe N, Ikuta K, Okazaki K, Nakase H, Tabata Y, Matsuura M, et al.&amp;nbsp;&lt;a href=&quot;http://www.springerlink.com/content/h6182upn47735620/abstract/&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: none; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Elimination of Local Macrophages in Intestine Prevents Chronic Colitis in Interleukin-10-Deficient Mice.&amp;nbsp;&lt;/a&gt;Digestive Diseases and Sciences. 2003;48(2):408–14.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Qualls JE, Tuna H, Kaplan AM, Cohen DA.&amp;nbsp;&lt;a href=&quot;http://onlinelibrary.wiley.com/doi/10.1002/ibd.20733/abstract&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: none; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Suppression of experimental colitis in mice by CD11c+ dendritic cells.&amp;nbsp;&lt;/a&gt;Inflammatory Bowel Diseases. 2009;15(2):236–47.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Mudter J, Neurath MF.&amp;nbsp;&lt;a href=&quot;http://onlinelibrary.wiley.com/doi/10.1002/ibd.20148/abstract&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: none; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;IL-6 signaling in inflammatory bowel disease: Pathophysiological role and clinical relevance.&amp;nbsp;&lt;/a&gt;Inflammatory Bowel Diseases. 2007;13(8):1016–23.&lt;/li&gt;
&lt;/ol&gt;
&lt;hr style=&quot;background-color: white; border-bottom-width: 0px; border-color: rgb(204, 204, 204); border-left-width: 0px; border-right-width: 0px; border-style: solid; clear: both; color: #050505; font-family: Arial; font-size: 14px; height: 0px; line-height: 23px; margin-bottom: 20px;&quot; /&gt;
&lt;h6 style=&quot;background-color: white; border: 0px; color: #373738; font-family: Arial; font-size: 1.2996em !important; font-weight: normal; line-height: 1.2em; margin: 15px 0px 2px; outline: 0px; padding: 0px 0px 2px; vertical-align: baseline;&quot;&gt;
Click reference to view publication summary.&lt;/h6&gt;
&lt;hr style=&quot;background-color: white; border-bottom-width: 0px; border-color: rgb(204, 204, 204); border-left-width: 0px; border-right-width: 0px; border-style: solid; clear: both; color: #050505; font-family: Arial; font-size: 14px; height: 0px; line-height: 23px; margin-bottom: 20px;&quot; /&gt;
&lt;h6 style=&quot;background-color: white; border: 0px; color: #373738; font-family: Arial; font-size: 1.2996em !important; font-weight: normal; line-height: 1; margin: 15px 0px 2px; outline: 0px; padding: 0px 0px 2px; vertical-align: baseline;&quot;&gt;
Publication 1.&lt;/h6&gt;
&lt;a href=&quot;http://www.clodrosome.com/2006-qualls-802/&quot; style=&quot;background-color: white; border: 0px; color: #002dcf; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px; outline: 0px; padding: 0px; text-decoration: none; vertical-align: baseline;&quot;&gt;Qualls JE, Kaplan AM, van Rooijen N, Cohen DA. Suppression of experimental colitis by intestinal mononuclear phagocytes. Journal of leukocyte biology. 2006;80(4):802–15. The contribution of innate immunity to inflammatory bowel disease (IBD) remains an area of intense interest. Macrophages (MØ) and dendritic cells (DC) are considered important ...&lt;/a&gt;
&lt;br /&gt;
&lt;br /&gt;
For more information visit:&lt;br /&gt;
&lt;br /&gt;
&lt;a href=&quot;http://www.clodrosome.com/&quot;&gt;www.clodrosome.com&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/2865769091467204992'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/2865769091467204992'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2012/08/intrarectal-administration-of.html' title='Intrarectal Administration of Clodronate Liposomes'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-6683233643012787402</id><published>2012-08-10T13:27:00.002-05:00</published><updated>2012-08-10T13:40:57.907-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Latest news from the liposome industry"/><title type='text'>The U.S. Food and Drug Administration today approved Marqibo (vincristine sulfate liposome injection)</title><content type='html'>&lt;br /&gt;
&lt;div style=&quot;background-color: white; border: none; color: #231f20; font-family: arial, helvetica, verdana; font-size: 14px; list-style: none; padding: 5px 0px; text-align: left;&quot;&gt;
&lt;b&gt;A great day for liposomologists!&lt;/b&gt;&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: none; color: #231f20; font-family: arial, helvetica, verdana; font-size: 14px; list-style: none; padding: 5px 0px; text-align: left;&quot;&gt;
&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: none; color: #231f20; font-family: arial, helvetica, verdana; font-size: 14px; list-style: none; padding: 5px 0px; text-align: left;&quot;&gt;
ENP Newswire - 10 August 2012&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: none; color: #231f20; font-family: arial, helvetica, verdana; font-size: 14px; list-style: none; padding: 5px 0px; text-align: left;&quot;&gt;
Release date- 09082012 - The U.S. Food and Drug Administration today approved Marqibo (vincristine sulfate liposome injection) to treat adults with a rare type of leukemia called Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL).&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: none; color: #231f20; font-family: arial, helvetica, verdana; font-size: 14px; list-style: none; padding: 5px 0px; text-align: left;&quot;&gt;
ALL is a rapidly progressing form of blood and bone marrow cancer that is more commonly diagnosed in children than adults. According to the National Cancer Institute, an estimated 6,050 men and women will be diagnosed with ALL and 1,440 will die from the disease this year.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: none; color: #231f20; font-family: arial, helvetica, verdana; font-size: 14px; list-style: none; padding: 5px 0px; text-align: left;&quot;&gt;
Marqibo is approved for patients whose leukemia has returned (relapsed) two or more times, or whose leukemia has progressed following two or more regimens of anti-leukemia therapy. Marqibo contains vincristine, a commonly used anti-cancer drug, encased within a liposome, a drug delivery vehicle composed of material similar to that of cell membranes. It is an injection administered once a week by a health care professional.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: none; color: #231f20; font-family: arial, helvetica, verdana; font-size: 14px; list-style: none; padding: 5px 0px; text-align: left;&quot;&gt;
&#39;Marqibo&#39;s approval demonstrates the FDA&#39;s commitment to the development and approval of drugs that address serious, unmet medical needs,&#39; said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA&#39;s Center for Drug Evaluation and Research. &#39;Marqibo provides an additional option for Philadelphia chromosome negative acute lymphoblastic leukemia patients whose disease is unresponsive to available therapies.&#39;&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: none; color: #231f20; font-family: arial, helvetica, verdana; font-size: 14px; list-style: none; padding: 5px 0px; text-align: left;&quot;&gt;
Marqibo is approved under the FDA&#39;s accelerated approval program, which allows the agency to approve a drug to treat a serious disease based on clinical data showing that the drug has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients. This program provides earlier patient access to promising new drugs while the company conducts additional clinical studies to confirm the drug&#39;s clinical benefit and safe use. Marqibo also received orphan-product designation by the FDA because it is intended to treat a rare disease or condition.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: none; color: #231f20; font-family: arial, helvetica, verdana; font-size: 14px; list-style: none; padding: 5px 0px; text-align: left;&quot;&gt;
The drug&#39;s effectiveness was evaluated in a single clinical trial in adult patients whose leukemia had relapsed at least two times despite standard treatments, and who had at least one previous treatment response lasting at least 90 days. The study objective was to determine the response rate to Marqibo, as either a complete remission (CR) or a complete remission with incomplete blood count recovery (CRi). Of 65 patients enrolled, 10 patients, or 15.4 percent, responded with either a CR or CRi. In the 10 patients achieving CR or CRi, the median duration of documented remission was 28 days. The median time to the first event of relapse, death, or next therapy was 56 days.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: none; color: #231f20; font-family: arial, helvetica, verdana; font-size: 14px; list-style: none; padding: 5px 0px; text-align: left;&quot;&gt;
The safety of Marqibo was evaluated in two single-arm trials of 83 patients who received the clinical treatment regimen. Serious adverse events such as low white blood cell counts with fever, low blood pressure, respiratory distress and cardiac arrest occurred in 76 percent of the patients studied. The most common side effects observed during clinical studies include constipation, nausea, low blood cell counts, fever, nerve damage, fatigue, diarrhea, decreased appetite, and insomnia.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: none; color: #231f20; font-family: arial, helvetica, verdana; font-size: 14px; list-style: none; padding: 5px 0px; text-align: left;&quot;&gt;
Prescribing information for Marqibo will carry a Boxed Warning alerting patients and health care professionals that the drug must be administered only through a vein (intravenously) because it is deadly if administered in other ways, such as into the spinal fluid. The Boxed Warning also states that Marqibo has different dosage recommendations than vincristine sulfate injection alone. To avoid overdose, it is important for health care professionals to verify the drug name and the dose before administration. Special requirements for preparation of the drug are detailed in the label.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: none; color: #231f20; font-family: arial, helvetica, verdana; font-size: 14px; list-style: none; padding: 5px 0px; text-align: left;&quot;&gt;
Marqibo is marketed by Talon Therapeutics Inc., based in South San Francisco, Calif.&lt;/div&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/6683233643012787402'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/6683233643012787402'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2012/08/he-us-food-and-drug-administration.html' title='The U.S. Food and Drug Administration today approved Marqibo (vincristine sulfate liposome injection)'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-4063226696960883503</id><published>2012-07-16T20:42:00.001-05:00</published><updated>2012-07-16T20:42:50.918-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodrosome"/><category scheme="http://www.blogger.com/atom/ns#" term="Macrophage depletion"/><title type='text'>Intradefect Administration of Clodronate Liposomes</title><content type='html'>&lt;br /&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; text-align: left; vertical-align: baseline;&quot;&gt;
We have identified only one reference to&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;intradefect administration&amp;nbsp;&lt;/strong&gt;of clodronate liposomes into injured bone, however other systemic routes of administration have been used to study the effects of osteal macrophage (osteomac) depletion on bone healing and remodeling as discussed on those pages and was employed in this study. In addition to injecting clodronate liposomes directly into the surgically-introduced “hole” in the mouse tibia immediately after the bone was injured, the liposomes were also dosed intraperitoneally (i.p.) daily for the 9 days between the bone injury and data collection. With this dosing regimen, some inflammatory macrophages would be recruited to the site of the injury releasing a limited concentration of inflammatory mediators prior to their death.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; text-align: left; vertical-align: baseline;&quot;&gt;
The authors did not investigate the possibility that pre-treatment of the mice 18-24 hours before the surgical intervention may have changed the outcome because this would have completely prevented the inflammatory phase (days 1-3) of bone healing. Likewise, withholding clodronate liposome treatment until after the inflammatory phase may have altered the results. Perhaps most importantly, the direct application of clodronate liposomes to the bone injury must have resulted in some level of free clodronate being released into the bone. Since the bone is not subject to a substantial rate of fluid exchange as in the bloodstream, the&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;free clodronate may have remained inside the bone&lt;/strong&gt;&amp;nbsp;for some time, plus the death of local macrophages which had phagocytosed clodronate liposomes will likely release more free clodronate for the first 18 hours or so post-clodronate liposome injection into the bone.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; text-align: left; vertical-align: baseline;&quot;&gt;
&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Osteoclasts are the target cells for systemically dosed free clodronate&lt;/strong&gt;, therefore we believe that&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;local osteoclasts may have also been depleted&lt;/strong&gt;&amp;nbsp;by the local clodronate liposome administration. While osteoclast depletion may or may not be a factor in this model, a free clodronate control group would have clarified whether or not osteoclast depletion could have affected the results. The authors were quite diligent by including a control liposome group, but we must emphasize that free clodronate can effect local cells in models that involve local administration of clodronate liposomes. It is only in situations, such as the bloodstream, where clodronate released from either the liposomes or dying macrophages is quickly diluted and removed from the extracellular space, that free clodronate can be ignored as a potential effector on phagocytic cells. The page on&amp;nbsp;&lt;a href=&quot;http://www.clodrosome.com/routes-of-administration/intrapulmonary/&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: none; vertical-align: baseline;&quot; title=&quot;Intrapulmonary&quot;&gt;intrapulmonary administration&lt;/a&gt;&amp;nbsp;of clodronate liposomes discusses this in detail. Liposomally-encapsulated clodronate when phagocytosed by cells is significantly more effective in killing macrophages, but free clodronate can be toxic to phagocytic cells—osteoclasts in particular.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; text-align: left; vertical-align: baseline;&quot;&gt;
With these factors in mind, we recommend thorough consideration of the&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;potential effects free clodronate after localized administration&lt;/strong&gt;&amp;nbsp;of clodronate liposomes including free clodronate control groups in models where free clodronate may not be effectively diluted and removed immediately after release from the liposomes or dying macrophages.&lt;/div&gt;
&lt;h6 style=&quot;border: 0px; color: #373738; font-family: Arial; font-size: 1.2996em !important; font-weight: normal; line-height: 1.2em; margin: 15px 0px 2px; outline: 0px; padding: 0px 0px 2px; vertical-align: baseline;&quot;&gt;
Click reference to view publication summary.&lt;/h6&gt;
&lt;hr style=&quot;border-bottom-width: 0px; border-color: rgb(204, 204, 204); border-left-width: 0px; border-right-width: 0px; border-style: solid; clear: both; color: #050505; font-family: Arial; font-size: 14px; height: 0px; line-height: 23px; margin-bottom: 20px;&quot; /&gt;
&lt;h6 ;=&quot;&quot; style=&quot;border: 0px; color: #373738; font-family: Arial; font-size: 1.2996em !important; font-weight: normal; line-height: 1; margin: 15px 0px 2px; outline: 0px; padding: 0px 0px 2px; vertical-align: baseline;&quot;&gt;
Publication 1.&lt;/h6&gt;
&lt;a href=&quot;http://www.clodrosome.com/2011-alexander-1511/&quot; style=&quot;border: 0px; color: #002dcf; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px; outline: 0px; padding: 0px; text-decoration: none; vertical-align: baseline;&quot;&gt;Alexander KA, Chang MK, Maylin ER, Kohler T, Müller R, Wu AC, van Rooijen N, Sweet MJ, Hume DA, Raggatt LJ, Pettit AR. Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. Journal of Bone and Mineral Research. 2011 Jul;26(7):1517–32. Bone-lining tissues contain a population of resident macrophages t...&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/4063226696960883503'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/4063226696960883503'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2012/07/intradefect-administration-of.html' title='Intradefect Administration of Clodronate Liposomes'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-697005146223484118</id><published>2012-07-10T18:43:00.001-05:00</published><updated>2012-07-10T18:44:29.099-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodrosome"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposome"/><category scheme="http://www.blogger.com/atom/ns#" term="Macrophage depletion"/><title type='text'>Precautions for Intravenous (IV) injection of Clodronate Liposomes</title><content type='html'>&lt;span style=&quot;color: #050505; font-family: Arial; font-size: 14px; line-height: 23px;&quot;&gt;Clodrosome is usually&amp;nbsp;&lt;/span&gt;&lt;strong style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;dosed intravenously to mice and rats in a relatively large volume,&amp;nbsp;&lt;/strong&gt;&lt;span style=&quot;color: #050505; font-family: Arial; font-size: 14px; line-height: 23px;&quot;&gt;or about 1% of their body weight. This, along with the fact that the Clodrosome suspension is slightly more viscous than water, increases the possibility of adverse reactions due to improper injection techniques. When injecting Clodrosome intravenously, the following guidelines will limit the potential for adverse reactions, including death. If the technician performing the injections is unfamiliar with injecting larger volumes (≥1% of the animals body weight) and/or viscous suspensions, it is useful for the technician to practice on non-experimental animals prior to initiation of the experimental protocol. Extra animals should be on hand should animals demonstrate suspicious behavior during or after Clodrosome treatment.&lt;/span&gt;&lt;br /&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; text-align: left; vertical-align: baseline;&quot;&gt;
&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; text-align: left; vertical-align: baseline;&quot;&gt;
These precautions listed below apply to any intravenous injection method or site since the liposomes will always initially pass through the lung capillary bed before they enter the arterial circulation for distribution throughout the animal. Prior to its expiration date, uncontaminated Clodrosome (which has been maintained according to package instructions) is not toxic when dosed intravenously to animals according to the following guidelines. Animals expiring during the experimental protocol for reasons unrelated to the model should be necropsied and examined for opportunistic infections or other causes of premature death. Premature deaths, outside of injection-related adverse reactions, cannot be attributed to Clodrosome treatment alone.&lt;/div&gt;
&lt;ol style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; list-style-image: initial; list-style-position: initial; margin: 0px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Plan the experimental setup and protocol keeping in mind that the animals receiving Clodrosome will become immune-suppressed within hours after treatment making sterile procedures for dosing and handling the animals more important than usual.&lt;ul style=&quot;background-color: transparent; border: 0px; list-style: disc; margin: 0px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;While full-blown immunocompromised animal containment is usually not necessary (depending on the size and potential for contamination in the facility), extra precautions need to be implemented, such as more frequently supplying clean bedding, water-bottles and food on a daily basis, as well as closely monitoring the animals for signs of infection or illness not related to the experimental model.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Take into account that Clodrosome-treated animals may succumb to infectious disease models at a higher rate than normal animals requiring shorter intervals for assessing the animals’ conditions.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;A significant number of unexpected deaths, outside of injection-related adverse reactions, should be investigated as it is likely due to opportunistic infections whose source must be eliminated from the facility environment or handling procedures.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Inflammation or necrosis at the injection site of only a few animals suggests contamination during the injection procedure while such reactions in several animals can be an indication that the clodronate liposome suspension has been contaminated. In this case the validity of the experiment should be seriously questioned.&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Generally, the maximum tolerable volume (ml) dosed to animals in a single, intravenous bolus should be limited to approximately 1% of the animal’s body weight in grams.&lt;ul style=&quot;background-color: transparent; border: 0px; list-style: disc; margin: 0px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;For example, the maximum volume dosed to a 20 g mouse is 0.2 ml. Many sources will cite more conservative guidelines of 5 ml/Kg (0.1 ml/20 g mouse) or a maximum 4-5% dilution of the total blood volume (TBV~1.2 ml/20 g mouse X 5% = 0.06 ml/mouse), however, if the technician is experienced in maintaining a slow, steady injection rate along with the other precautions listed here, the larger volume is well tolerated.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;In the event that the investigator suspects that injection-related adverse events are interfering with the study, Clodrosome can be diluted and dosed via intravenous infusion or smaller doses may be evaluated for effectiveness. However, this is rarely necessary.&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Clodrosome should be at RT for dosing to healthy animals; infected or otherwise compromised animals (i.e. SCID or nude mice) may require Clodrosome be warmed to the animal’s body temp prior to injection.&lt;ul style=&quot;background-color: transparent; border: 0px; list-style: disc; margin: 0px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Animals that are dosed intravenously with larger volumes of cold fluids can go into hypothermic shock.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Note that Clodrosome should be maintained at 4°C as much as possible. Consider making a sterile transfer of the total volume required for a single experiment from the original vial to another sterile container which can be warmed to the appropriate temperature, if the animal dosing protocol is expected to require Clodrosome to be maintained at elevated temperature for longer than an hour.&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Immediately before extracting Clodrosome from the vial, visually inspect the suspension, making sure that it is homogeneous with no visible particulates.&lt;ul style=&quot;background-color: transparent; border: 0px; list-style: disc; margin: 0px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Occasionally, liposomes will “settle” toward the bottom of the vial in which case the vial should be slowly and smoothly inverted several times.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Never vigorously shake liposomes; they will not “break”, but lipid-stabilized air bubbles can be introduced into the suspension. If these are transferred into the syringe and dosed to an animal, it could be seriously injured or killed by&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;air emboli&amp;nbsp;&lt;/strong&gt;(air bubbles introduced into the bloodstream).&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Also visually inspect Clodrosome once it is drawn into the syringe to ensure that no air bubbles have been introduced during its extraction from the vial. Following proper syringe-filling and air-bubble-removal procedures should prevent any incidents due to air emboli.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Some claim that air emboli are only an issue when introduced into arteries and that venous air emboli diffuse into the lungs when passing through the lung capillary bed, however many report adverse reactions when suspensions containing air bubbles are injected intravenously.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;It is probable that air-bubbles in the Clodrosome suspension are stabilized by a monolayer of lipid, and therefore may not be as readily dissolved as air bubbles in an aqueous solution. This is characteristic of liposome suspensions and does not indicate a quality issue with Clodrosome. However, if a substantial increase in bubbles or foam is noticed with older Clodrosome suspensions, it may be an indication of degraded lipid and the Clodrosome should not be used.&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;The other important reason for removing all air bubbles is that included&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;air bubbles occupy space in the needle and syringe&amp;nbsp;&lt;/strong&gt;so that the volume of suspension in the needle/syringe is less than the measured volume.&lt;ul style=&quot;background-color: transparent; border: 0px; list-style: disc; margin: 0px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Syringes are calibrated to deliver the indicated volume with the syringe tip and needle hub completely filled.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;It is not an issue when dosing Clodrosome directly from the vial, but the dead volume in a 1 ml syringe and needle hub is substantial (70 µl) compared to the 100-200 µl dose intended for mice. If this dead volume is not taken into account when using a single 1 ml syringe to draw up and/or dilute a suspension within the syringe, significant dosing errors can occur [11].&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;If necessary, a temporary&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;engorgement of the vein&amp;nbsp;&lt;/strong&gt;may make the injection easier.&lt;ul style=&quot;background-color: transparent; border: 0px; list-style: disc; margin: 0px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;For example, some technicians briefly dip the tail into warm—not HOT—water in order to make the vein more prominent; warm compresses may be applied to rabbit ears; tourniquets are appropriate for use on limbs in dogs.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Some technicians place animals under heat lamps, but this is discouraged, especially in small rodents, as the animals are often overheated leading to additional trauma and discomfort.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;If the vein is not easily visualized or accessed, consider using another injection route, such as retro-orbital injection as described above.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Remember that any change in protocol usually must be approved by the institutional animal care and use committee, therefore it is often useful to include alternative injection sites and/or methods in the initial application to the committee.&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Once the needle is inserted into the tail vein,&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;slowly and steadily inject the suspension at a rate of no more than 1 ml/minute.&amp;nbsp;&lt;/strong&gt;This translates to taking about 12-15 seconds to inject a 0.2 ml dose volume. Should the animal become overly agitated or begin gasping for air as discussed above, further decrease the injection rate. The slow injection rate allows the liposome suspension to be thoroughly mixed into the blood so that they are properly opsonized for optimal phagocyte uptake.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;The animals should be closely observed for a few minutes for adverse reactions after the injection is completed and the animal returned to the cage. The investigator should consider excluding animals from the study which demonstrate significant aberrant behavior.&lt;/li&gt;
&lt;/ol&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/697005146223484118'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/697005146223484118'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2012/07/precautions-for-intravenous-iv.html' title='Precautions for Intravenous (IV) injection of Clodronate Liposomes'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-6571878629028507289</id><published>2012-07-09T19:28:00.001-05:00</published><updated>2013-01-04T16:58:31.849-06:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodrosome"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposome"/><category scheme="http://www.blogger.com/atom/ns#" term="Macrophage depletion"/><title type='text'>Systemic Administration of Clodronate Liposomes via Intravenous (IV) Injection</title><content type='html'>&lt;div style=&quot;text-align: left;&quot;&gt;
&lt;div style=&quot;border: 0px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;div style=&quot;color: #050505; font-family: Arial; font-size: 14px; line-height: 23px;&quot;&gt;
&lt;span style=&quot;background-color: white;&quot;&gt;We are continuing to review publications related to intravenously injected clodronate liposomes. This discussion will be updated with any pertinent information as we find it or whenever new information is published.&lt;/span&gt;&lt;/div&gt;
&lt;h2 style=&quot;color: #050505; font-family: Arial; font-size: 14px; line-height: 23px;&quot;&gt;
&lt;span style=&quot;background-color: white;&quot;&gt;&lt;b&gt;Summary&lt;/b&gt;&lt;/span&gt;&lt;/h2&gt;
&lt;div&gt;
&lt;span style=&quot;background-color: white; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px;&quot;&gt;The intravenous route of administration is used in almost half of the published studies on liposomal clodronate. Using intravenous injection of clodronate liposomes limits their access to the liver, spleen and bone marrow along with circulating monocytes. Clodronate liposomes have access to the phagocytic cells of these tissues through specialized vasculature known as sinusoids but cannot otherwise leave the vascular system in normal, healthy animals. The liver and splenic sinusoids possess a discontinuous basement membrane which allow not only liposomes, but also pathogens, large proteins and cells to exit the circulation, however the bone marrow sinusoids have no basement membrane. Endothelial cells lining the bone marrow sinusoids are supported by the constituent cells of the bone marrow such that when the bone marrow is depleted by radiation or chemotherapy, the sinusoids collapse and reappear only when the bone marrow is regenerated.&lt;/span&gt;&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Small liposomes (&lt;200 allow=&quot;allow&quot; and=&quot;and&quot; areas=&quot;areas&quot; can=&quot;can&quot; cells.=&quot;cells.&quot; endothelium=&quot;endothelium&quot; escape=&quot;escape&quot; extravasation=&quot;extravasation&quot; in=&quot;in&quot; induce=&quot;induce&quot; inflammatory=&quot;inflammatory&quot; larger=&quot;larger&quot; mediators=&quot;mediators&quot; nm=&quot;nm&quot; of=&quot;of&quot; p=&quot;p&quot; proteins=&quot;proteins&quot; the=&quot;the&quot; to=&quot;to&quot; vasculature=&quot;vasculature&quot; where=&quot;where&quot;&gt;&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Monocytes can act as “trojan horses” in delivering drugs that have been released from previously phagocytosed liposomes by leaving the vasculature and maturing into tissue macrophages as is their normal fate, or the migration may be in response to inflammation. This is not usually a mechanism for clodronate delievery by clodronate liposomes except when they are locally administered in certain tissues such as the CNS, intrapulmonary space or possibly bone marrow where influx/efflux of water-soluble molecules is limited.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Intravenous injection of clodronate liposomes in rodents is typically accomplished through the lateral tail vein, but retro-orbital intravenous access is considered by some to be a superior method for intravenous delivery. Regardless of the access site, intravenously injected liposomes initially pass through the lung capillary beds before being circulated throughout the rest of the body from the aorta. The liposomes continue to circulate until removed by the phagocytic cells of the tissues mentioned above. Familiarity and consideration of the circulation route of liposomes will allow scientists to better understand and utilize liposomal clodronate in their studies.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Using the proper dosing technique along with appropriate storage and handling of Clodrosome as described below will ensure the maximum depletion results with no adverse effects in treated animals. Clodrosome is not inherantly toxic to animals when used as directed. Unexpected deaths cannot be attributed to Clodrosome; improper dosing methods and opportunistic infections are two of the major causes of unexplained deaths in Clodrosome-treated animals.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Enhanced monocyte margination due to clodronate liposome administration or as a result of some pathogenic or inflammatory models must be considered when evaluating monocyte depletion as well as when monitoring blood levels of cytokines. Marginated monocytes are known to release higher levels of certain cytokines into the bloodstream, therefore the correlation between circulating monocyte counts and cytokine levels may not be accurate.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
When liposomes or other particles are injected into animals at sufficient doses, the phagocytic cells of the reticuloendothelial system (RES) become saturated and unable to take up more particles until their current load is digested or otherwise sequestered. This state, known as RES blockade, may be used as a method of enhancing the circulation time of liposomes or it may explain differences in the effects/biodistribution of liposomes after multiple injections.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
If clodronate liposomes are being used for complete systemic depletion of macrophages, the rate of repopulation of the phagocytes within the various organs and blood must be taken into account, especially considering that monocyte counts begin to increase between 24-30 hours in mice while liver and splenic macrophages may remain depleted for up to a week or more. During repopulation, the relative levels of various subpopulations of phagocytes can be considerably different from steady state distributions.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Depletion of macrophages via intravenous administration of clodronate liposomes is usually a “means to an end” rather than the focus of most published studies, however unless the behavior of the liposomes and the depletion/repopulation pattern in the chosen model in the chosen species has been well characterized in previous studies, these data may need to be collected during the course of the study. Consideration of the appropriate depletion controls and limiting “assumptions” will allow for unambiguous interpretations of resulting data.&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;b&gt;Discussion:&lt;/b&gt;&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
The most common method of dosing clodronate liposomes is by intravenous injection; about half of all clodronate liposome studies published thusfar use the intravenous administration route. Direct administration into the bloodstream ensures that all phagocytes having direct access to the blood can potentially engulf clodronate liposomes. However, just as with all liposomal drug delivery, the liver and spleen are so highly efficient in removing foreign particles from the bloodstream, the exposure of phagocytes outside of these organs to blood-borne clodronate liposomes can be limited.&lt;/div&gt;
&lt;table align=&quot;center&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; class=&quot;tr-caption-container&quot; style=&quot;color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;tbody&gt;
&lt;tr&gt;&lt;td style=&quot;text-align: center;&quot;&gt;&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhhosfbV2-Qpn25tpARiQ2HgPycGjht6UHHMatAHPvQ7q7kKWVdvL3DlHEbfRfZZrs4_xUiANVb3DRIIl4rq1m-pqvUtgEctKwg1kzqvTQKVQwix2ornNMOAoMnblW_qsHNNdRoZNrhe2c/s1600/Liver-Sinusoid.png&quot; imageanchor=&quot;1&quot; style=&quot;margin-left: auto; margin-right: auto;&quot;&gt;&lt;img border=&quot;0&quot; height=&quot;400&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhhosfbV2-Qpn25tpARiQ2HgPycGjht6UHHMatAHPvQ7q7kKWVdvL3DlHEbfRfZZrs4_xUiANVb3DRIIl4rq1m-pqvUtgEctKwg1kzqvTQKVQwix2ornNMOAoMnblW_qsHNNdRoZNrhe2c/s400/Liver-Sinusoid.png&quot; width=&quot;355&quot; /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;tr-caption&quot; style=&quot;text-align: center;&quot;&gt;&lt;strong style=&quot;background-color: #f3f3f3; border: 0px; color: #050505; font-size: 11px; line-height: 17px; margin: 0px; outline: 0px; padding: 0px; text-align: left; vertical-align: baseline;&quot;&gt;Diagram of hepatic sinusoid, one of the three types of organ sinusoidal regions where liposomes can escape the vasculature in normal, healthy animals. For most clodronate liposome applications, the majority of the injected dose will leave the bloodstream through the hepatic sinusoids.&lt;/strong&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
&lt;div style=&quot;background-color: white; border: 0px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Unmodified, micron-sized clodronate liposomes will be quickly removed from the bloodstream, usually in less than 1 hour. Having said this, liposomes cannot leave the bloodstream through veins and arteries. In normal animals, the&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;only areas where liposomes can interact with cells&amp;nbsp;&lt;/strong&gt;outside the vascular system is in the&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;sinusoidal&amp;nbsp;&lt;/strong&gt;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;capillaries of the spleen, liver and bone marrow&amp;nbsp;&lt;/strong&gt;[1]; sinusoidal capillaries are a type of fenestrated capillaries (containing small holes or&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;fenestrae&lt;/em&gt;) with a very loose structure, little basement membrane and large fenestrae which allow equally large molecules, cells and pathogens to pass through their walls.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Bone marrow and its sinusoids comprise a unique environment.&amp;nbsp;&lt;/strong&gt;The bone marrow (BM) was also thought to be composed of sinusoidal capillaries located within the marrow sinus similarly to other components of the mononuclear phagocyte system (MPS, aka RES, or reticuloendothelial system), but the size of these fenestrae have been reported to be only 85-150 nm in mice and therefore only accessible to liposomes in the ≤120 nm range. The predominant mode of larger liposome uptake by bone marrow appeared to be by the perisinal macrophages&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;&lt;/strong&gt;which extend pseudopodia between the endothelial cells and into the marrow sinus [2, 3, 4] in order to capture blood-borne particles, including damaged RBC, although this mechanism has only been directly observed in rabbits and marmosets. However, given that larger liposomes do indeed enter the bone marrow in rats and mice, we assumed that all bone marrow sinusoids have some mechanism by which macrophages come into contact with intravenous liposomes sized in the micron range. These authors also warn that there appears to be a large disparity between species when looking at the mechanisms of bone marrow uptake with mice and rats prone to limited marrow uptake of liposomes when compared to rabbits and larger mammals.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
This rather confusing description of bone marrow sinusoids was clarified by Kopp,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&amp;nbsp;&lt;/em&gt;who describe BM sinusoids as having no basement membrane unlike other vascular components [19]. They describe marrow sinusoids as being lined by specialized bone marrow endothelial cells (BMEC) which are only supported by the cells of the bone marrow including hematopoetic stem cells and progenitor cells. Furthermore, unlike other vascular tissues in which the vascular endothelial cells are supported by a collagenous basement membrane, the BM sinusoids disappear when the cells of the BM are destroyed by radiation or certain chemotherapies as there is no other scaffolding to support the BMEC forming the sinusoids. The sinusoids are reconstructed as the BM is replenished. Therefore, access to the BM is dependent upon BMEC adhesion molecules (P-selectin, E-selectin, VCAM-1) and the various signalling events which induce the BMEC to separate from each other thus allowing access to the BM. The absence of the basement membrane suggests that there is no size restriction in the uptake of blood-borne particles into the BM.&lt;/div&gt;
&lt;table align=&quot;center&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; class=&quot;tr-caption-container&quot; style=&quot;color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;tbody&gt;
&lt;tr&gt;&lt;td style=&quot;text-align: center;&quot;&gt;&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEieiuj8XS1aR0kGkO9XwxObfuKx3M-1_i8rGmSfg8op1qOHULm0ntTRbyzZRtndXc1GzoRtvF0-VWVoOsaSulEGGgD0Tt1UXDiqxyY12_KSA1FiKZFg5uHv3rOg_AdZZQne6mJJ-bJEgcc/s1600/Bone-Model.png&quot; imageanchor=&quot;1&quot; style=&quot;margin-left: auto; margin-right: auto;&quot;&gt;&lt;img border=&quot;0&quot; height=&quot;318&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEieiuj8XS1aR0kGkO9XwxObfuKx3M-1_i8rGmSfg8op1qOHULm0ntTRbyzZRtndXc1GzoRtvF0-VWVoOsaSulEGGgD0Tt1UXDiqxyY12_KSA1FiKZFg5uHv3rOg_AdZZQne6mJJ-bJEgcc/s400/Bone-Model.png&quot; width=&quot;400&quot; /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;tr-caption&quot; style=&quot;text-align: center;&quot;&gt;&lt;strong style=&quot;background-color: #f3f3f3; border: 0px; color: #050505; font-size: 11px; line-height: 17px; margin: 0px; outline: 0px; padding: 0px; text-align: left; vertical-align: baseline;&quot;&gt;Hematopoetic stem cell niche as described by Lévesque,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&amp;nbsp;&lt;/em&gt;[17] including the bone marrow mononuclear phagocyte populations (yellow) investigated by Chow,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&amp;nbsp;&lt;/em&gt;[16] which regulate HSC mobilization. Many cell types, such as osteoprogenitors, which occupy the BM have been omitted for clarity.&lt;br /&gt;&lt;/strong&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
&lt;div style=&quot;border: 0px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;span style=&quot;color: #050505; font-family: Arial;&quot;&gt;&lt;span style=&quot;font-size: 14px; line-height: 23px;&quot;&gt;More recently a bone marrow macrophage subtype, known as the&lt;/span&gt;&lt;/span&gt;&lt;strong style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;osteomac,&amp;nbsp;&lt;/strong&gt;&lt;span style=&quot;color: #050505; font-family: Arial;&quot;&gt;&lt;span style=&quot;font-size: 14px; line-height: 23px;&quot;&gt;has been reported susceptible to intravenous clodronate liposome depletion by the retro-orbial route [14]. Osteomacs and other bone marrow macrophages (CD169+) have been shown by at least 2 groups to be key players in controlling in the release of hematopoetic stem cells (HSC) into the circulation [15, 16] leading to the suggestion that intravenously delivered clodronate liposomes may be used to increase stem cell recovery in the blood post-treatment by granulocyte colony stimulating factor (G-CSF). G-CSF is used to stimulate production of hematopoetic stem and progenitor cells for collection prior to transplantation.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Looking at the diagram of the HSC niche proposed by Lévesque,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&lt;/em&gt;[17] which describes osteomacs as forming a dome-like structure atop the osteoblasts, we are curious about the remote location of the osteomacs from the marrow sinusoid where intravenously administered liposomes would access the bone marrow. It has been shown that liposomes tend not to migrate into tumors from the region where they extravasate [18], therefore it seems unlikely that a clodronate liposome could migrate from the sinusoid located in the central bone marrow to the endosteum for uptake by osteomacs. It seems much more probable that the perisinusoidal macrophages would be responsible for the initial uptake of clodronate liposomes from the bloodstream.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
This would further lead us to speculate that clodronate liposome uptake by BM macrophages around or in the sinusoid may trigger a signaling event which solicits the osteomacs toward the sinusoid. This sort of osteomac migration toward the sinusoid is observed post-treatment with G-CSF and appears to accompany the activation and release of HSC into the circulation along with depletion of osteoblasts [14]. Once in the perisinusoidal region, osteomacs may then have access to blood-borne liposomes entering the BM sinusoid. A more remote possibility, although one which needs to be investigated, is that clodronate released from dying macrophages within the bone marrow may reach concentrations which could affect the osteomacs either in their base location on the endosteal osteoblast monolayer or possibly after their migration toward the sinusoid.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
In either case, we suspect that the mobilization of HSC from the niche is not dependent upon clodronate liposome depletion of osteomacs, rather due to clodronate liposome effects on other bone marrow macrophages (possibly the CD169+ macrophages identified by Chow,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&amp;nbsp;&lt;/em&gt;?), which in turn elicit migration of the osteomacs toward the BM sinusoid where they may become susceptible to clodronate liposome depletion.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Application of fluorescently-labeled liposomes to this model should shed light on precisely which populations of bone marrow macrophages phagocytose liposomes, where within the niche the uptake occurs and ultimately, whether or not osteomac depletion by clodronate liposomes plays a direct role in HSC mobilization.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
This is an example of how important it is to carefully consider the possible, or most likely, areas where liposomes can and cannot leave the vasculature as well as what happens to them when they have the opportunity to interact with extravascular tissues. For the most part, any tissue interaction is limited to phagocytic uptake since liposomes (including so-called “stealth” liposomes) have not been shown to migrate from the immediate perivascular region although their contents can be transported by migrating macrophages.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
It is also imperative to no longer consider a liposome, which has been phagocytosed, to be a liposome. Once internalized, liposomes are destined to be digested by the phagocyte, in which case the encapsulated cargo may be delivered by the macrophage as discussed later on this page. Even liposomes designed to be resistant to lysosomal degradation appear to remain inside a terminal endosome. We are not aware of any plausible reports of phagocytosed liposomes “reappearing” as an intact liposome as some seem to suggest.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Another point which we constantly reiterate is not a “given”, is the assumption that unencapsulated or free clodronate is not toxic or otherwise has no effect on cells in general. Free clodronate has been shown to be toxic to macrophages&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;in vitro&lt;/em&gt;, albeit at higher concentrations than required for liposomal clodronate toxicity, and elicit morphological changes in pulmonary endothelial cells&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;in vivo&amp;nbsp;&lt;/em&gt;(see discussion on the&amp;nbsp;&lt;a href=&quot;http://www.clodrosome.com/routes-of-administration/intrapulmonary/&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot; title=&quot;Intrapulmonary&quot;&gt;Intrapulmonary&lt;/a&gt;administration page). In fact, the only cells with demonstrated susceptibility to intravenously injected free clodronate are osteoclasts. The authors investigating bone marrow phagocyte depletion with clodronate liposomes above assume that free clodronate released from dying macrophages within the BM has no effect on the surrounding cells, however given that the bone marrow constituents, especially those located toward the endosteal region (remote from the blood flow in the sinusoid), experience a much more limited exchange rate of extracellular molecules, including oxygen, it is conceivable that clodronate release from dead/dying macrophages could result in a substantial concentration of free clodronate in the region. While we cannot cite any specific data in these studies that would indicate a substantial contribution of free clodronate, we believe that the presence of free clodronate in the BM is a distinct possibility and that the effects of liposomal and free clodronate on the various cell types in the bone marrow should be investigated. For example, Kellinsalmi,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&amp;nbsp;&lt;/em&gt;have demonstrated clodronate-induced inhbition of calcium deposition by human MSC-derived osteoblasts at concentrations as low as 1 nM [21].&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Bone marrow targeting of liposomes has been reported using a unique liposome formulation containing carboxylic-acid based lipids, which display succinate on the surface of the liposome, as the targeting moiety [2] although this targeting mechanism has not been applied to clodronate liposomes to date.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Sites of Inflammation Allow Smaller Liposomes to Escape the Vasculature.&amp;nbsp;&lt;/strong&gt;If any site(s) of inflammation are present in the animal,&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;inflammatory mediators cause vascular endothelial cells to separate&amp;nbsp;&lt;/strong&gt;(where they are normally closely associated by&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;tight junctions&lt;/strong&gt;) forming openings in the capillaries as large as 400 nm. Therefore, liposomes that are smaller than these openings can escape the vasculature in areas of inflammation including solid tumors, focal infections, tissue injury, etc. A similar situation exists in areas of&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;angiogenesis&amp;nbsp;&lt;/strong&gt;(new capillary growth) commonly found in solid tumors and damaged tissue where inflammation will also be a factor. This is the basis of passive targeting of smaller liposomes, however for most applications of clodronate liposomes, micron-sized clodronate liposomes only leave the vasculature through the spleen, liver and bone marrow sinusoids where they are predominantly phagocytosed by specialized macrophages (Kupffer cells in the liver, marginal zone macrophages of the spleen, and perisinusoidal macrophages of the bone marrow).&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Monocytes and Macrophages Can Deliver&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Liposomal Contents,&amp;nbsp;&lt;/em&gt;but&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Not Liposomes.&amp;nbsp;&lt;/em&gt;&lt;/strong&gt;Another mechanism by which liposomal contents can be delivered to tissues is often known as the&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;trojan horse mechanism.&amp;nbsp;&lt;/em&gt;Monocytes that have phagocytosed liposomes&amp;nbsp;&lt;/strong&gt;in the bloodstream, then migrate into tissues for maturation into tissue macrophages serve as the&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;trojan horses.&amp;nbsp;&lt;/em&gt;Of course, this mechanism is dependent upon the active liposomal drug being able to escape the monocyte/macrophage into surrounding tissue, or in the case of many pathogens, the monocyte/macrophage phagocytosing the pathogen which is then killed by the liposomal drug previously taken up by the monocyte from the bloodstream. This mechanism has been reported as responsible for delivering serotonin across the blood-brain barrier [12]. Clodronate liposomes can be used to verify the trojan horse mechanism by demonstrating that the drug or other compound is not delivered to the extravascular tissue in the absence of monocytes which have been depleted by clodronate liposomes.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Scientists also question the possibility of&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;clodronate delivery by monocytes/macrophages&amp;nbsp;&lt;/strong&gt;(especially dying cells). In most cases where the clodronate liposomes have been dosed systemically (i.v. or i.p.), free clodronate released either from the liposomes or dying phagocytes is quickly diluted and excreted so that other cells are not exposed to free clodronate. Additionally, free clodronate cannot access the cytosol of most cells and in cases where it has been delivered intracellularly to cells other than mononuclear phagocytes (i.e. neutrophils, eosinophils), it doesn’t appear to be toxic to those other cell types [13]. However, in the case of many local delivery methods for clodronate liposomes, released clodronate may not be quickly diluted or otherwise removed from the site (see detailed discussion on the&amp;nbsp;&lt;a href=&quot;http://www.clodrosome.com/routes-of-administration/intrapulmonary/&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot; title=&quot;Intrapulmonary&quot;&gt;Intrapulmonary&amp;nbsp;&lt;/a&gt;administration page), in which case the effect of free clodronate must be investigated with the appropriate controls. As discussed above, the bone marrow may be another location in which clodronate may accumulate when released from dead/dying macrophages, however this hypothesis has not been proven nor disproven to date.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Free clodronate controls should always be considered and/or investigated&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;in vitro&amp;nbsp;&lt;/em&gt;since the released clodronate may achieve substantial concentrations because the incubation conditions provide a limited dilution and the clodronate has no avenue for removal from the medium. While liposomal clodronate usually demonstrates an IC&lt;sub&gt;50&amp;nbsp;&lt;/sub&gt;(concentration required to kill 50% of the cells or limit the growth of cells by 50%) of an order of magnitude higher than free clodronate, the experimental protocol should take into account the possibility of&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;clodronate release from liposomes or dead/dying cells reaching a concentration that will effect the cultured cells.&lt;/strong&gt;&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Alternative Sites of Intravenous Injections.&amp;nbsp;&lt;/strong&gt;Many investigators only consider the&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;lateral tail vein&amp;nbsp;&lt;/strong&gt;as an injection site for intravenous liposome dosing and it is the most common route used in rodents. However, some advocate&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;intravenous injection via the retro-orbital sinus&lt;/strong&gt;(abbreviated RO) as more humane, less traumatic and easier to master [5, 6] than tail-vein injections, while other institutional animal use and care committees require additional justification for utilizing this route of intravenous administration. Of course, many animals do not have tails that enclose large, accessible veins. Rabbits are usually injected through a marginal ear vein, guinea pigs and hamsters through the penile vein and dogs through the cephalic or saphenous veins, although many species can be injected retro-orbitally; proponents suggest that the negative visual image of an animal being injected “in the eye” is the primary reason that this technique is not more commonly used. The method is preferred by some for small animal radionuclide studies (preclinical studies, in particular) as faster and less prone to accidental dissemination of radioactive compounds [7, 8]. The technique appears to be superior to tail-vein injections (or other venous routes) for neonatal mice and C57BL/6, or other dark-colored mice, for which the lateral tail veins are more difficult to visualize. The same dose-volume considerations apply to RO injections as tail-vein injections and the&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;same dose volume is used regardless of the injection site.&amp;nbsp;&lt;/strong&gt;Retro-orbital intravenous delivery of clodronate liposomes has been used in several studies including those performed on hamsters [9] and mice [10]. Studies comparing retro-orbital and lateral tail vein injections conclude that there are no detectable differences in delivery of most compounds dosed by the two methods.&lt;/div&gt;
&lt;table align=&quot;center&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; class=&quot;tr-caption-container&quot; style=&quot;color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;tbody&gt;
&lt;tr&gt;&lt;td style=&quot;text-align: center;&quot;&gt;&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiUBs5J5evw4JbHNDOUMngWOLlO_6dsXdSSc4c2HoaNOFFTv4uog5RGODT06dxDI496QaJXlKGckG6uH8DYNaffTGgYKDEqJqWb1ZfsxJJZmwUDkCMAO-5pthqnkDnINz0nJXrvZQRx8TQ/s1600/Circulation.png&quot; imageanchor=&quot;1&quot; style=&quot;margin-left: auto; margin-right: auto;&quot;&gt;&lt;img border=&quot;0&quot; height=&quot;640&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiUBs5J5evw4JbHNDOUMngWOLlO_6dsXdSSc4c2HoaNOFFTv4uog5RGODT06dxDI496QaJXlKGckG6uH8DYNaffTGgYKDEqJqWb1ZfsxJJZmwUDkCMAO-5pthqnkDnINz0nJXrvZQRx8TQ/s640/Circulation.png&quot; width=&quot;457&quot; /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;tr-caption&quot; style=&quot;text-align: center;&quot;&gt;&lt;strong style=&quot;background-color: transparent; border: 0px; font-size: 14px; margin: 0px; outline: 0px; padding: 0px; text-align: left; vertical-align: baseline;&quot;&gt;From the Liposome’s Point of View&lt;/strong&gt;&lt;span style=&quot;font-size: 14px; text-align: left;&quot;&gt;…Consideration of&lt;/span&gt;&lt;span style=&quot;font-size: 14px; text-align: left;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;strong style=&quot;background-color: transparent; border: 0px; font-size: 14px; margin: 0px; outline: 0px; padding: 0px; text-align: left; vertical-align: baseline;&quot;&gt;the circulation route&amp;nbsp;&lt;/strong&gt;&lt;span style=&quot;font-size: 14px; text-align: left;&quot;&gt;of liposomes (shown here) post-injection may decrease the gap in expectations vs. results when dosing liposomes. This diagram will also verify our previous statement that there is effectively no difference in the liposome circulation route dependent upon the intravenous injection site reiterating that liposomes cannot leave the circulation through larger veins or arteries. After injecting liposomes into any venous site, the&lt;/span&gt;&lt;span style=&quot;font-size: 14px; text-align: left;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;strong style=&quot;background-color: transparent; border: 0px; font-size: 14px; margin: 0px; outline: 0px; padding: 0px; text-align: left; vertical-align: baseline;&quot;&gt;first capillary bed that they encounter is in the lungs&amp;nbsp;&lt;/strong&gt;&lt;span style=&quot;font-size: 14px; text-align: left;&quot;&gt;from the right ventricle of the heart. Therefore, if the liposomes are aggregated or too large to pass through the lung capillaries, the animal will show signs of respiratory distress immediately after injection of the liposomes; avoiding respiratory distress when dosing clodronate liposomes intravenously is discussed in detail later on this page.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
&lt;div style=&quot;border: 0px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
After passing through the lung capillary bed where the CO&lt;sub&gt;2&lt;/sub&gt;-O&lt;sub&gt;2&amp;nbsp;&lt;/sub&gt;exchange takes place, the liposomes continue into the left atrium, then left ventricle, of the heart and are&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;distributed throughout the body from the aorta.&lt;/strong&gt;A portion of the liposome dose will distribute into all arteries throughout the body and pass through the various organ capillary beds prior to re-entering the venous circulation. As discussed above, in a normal, healthy animal, clodronate liposomes will not leave the vasculature except in the spleen, liver or bone marrow. Thus, the&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;vast majority of the liposome dose which enters the subclavian and jugular arteries&amp;nbsp;&lt;/strong&gt;and circulates through the upper portion of the body will return to the right heart. Only a very small portion of these liposomes will be taken up by the bone marrow in the upper torso. Likewise,&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;most liposomes which enter into the renal and iliac arteries&amp;nbsp;&lt;/strong&gt;will return to the right heart where these liposomes will begin their&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;second pass&amp;nbsp;&lt;/strong&gt;through the body with a slightly larger number of liposomes being taken up by the larger bones’ marrow in the lower body than in the upper body.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
The&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;majority of the clodronate liposome dose which enter the mesenteric and celiac arteries will be retained in the spleen and liver.&amp;nbsp;&lt;/strong&gt;While we have been unable, thusfar, to locate specific information on the blood flow distribution in rodents and other common lab species (i.e. what proportion of the blood leaving the aorta enters the mesenteric and coeliac arteries and is filtered through the liver during the first pass?)&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;most of the clodronate liposomes will be filtered out by the spleen, liver and bone marrow within the first few passes.&amp;nbsp;&lt;/strong&gt;Of course, if these were 100 nm liposomes and included PEG on the surface, some would continue to circulate for a couple of days or more. However, clodronate liposomes are designed to leave the circulation quickly through phagocytosis.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
While we have generally referred to the&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;entire&amp;nbsp;&lt;/em&gt;liposome dose and&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;all&amp;nbsp;&lt;/em&gt;of the liposomes, it is important to note that some of these&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;liposomes will be destroyed upon entering the bloodstream.&amp;nbsp;&lt;/strong&gt;This means that if we were to attempt to identify the location of the entire injected clodronate liposome dose at any given time, we could never recover 100% of the injected dose (even outside of experimental error) because a certain portion (dependent upon the composition and morphology) of the liposomes will succumb to disruption by various serum proteins. This phenomenon is not usually of any consequence when dosing clodronate liposomes, but it is a factor is often excluded when considering the fate of intravenously administered liposomes.&lt;/div&gt;
&lt;h2 style=&quot;color: #050505; font-family: Arial; font-size: 14px; line-height: 23px;&quot;&gt;
Intravenous Injection Precautions&lt;/h2&gt;
&lt;div style=&quot;color: #050505; font-family: Arial; font-size: 14px; line-height: 23px;&quot;&gt;
Clodrosome is usually&amp;nbsp;&lt;strong style=&quot;border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;dosed intravenously to mice and rats in a relatively large volume,&amp;nbsp;&lt;/strong&gt;or about 1% of their body weight. This, along with the fact that the Clodrosome suspension is slightly more viscous than water, increases the possibility of adverse reactions due to improper injection techniques. When injecting Clodrosome intravenously, the following guidelines will limit the potential for adverse reactions, including death. If the technician performing the injections is unfamiliar with injecting larger volumes (≥1% of the animals body weight) and/or viscous suspensions, it is useful for the technician to practice on non-experimental animals prior to initiation of the experimental protocol. Extra animals should be on hand should animals demonstrate suspicious behavior during or after Clodrosome treatment.&lt;div style=&quot;border: 0px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;/div&gt;
&lt;div style=&quot;border: 0px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
These precautions listed below apply to any intravenous injection method or site since the liposomes will always initially pass through the lung capillary bed before they enter the arterial circulation for distribution throughout the animal. Prior to its expiration date, uncontaminated Clodrosome (which has been maintained according to package instructions) is not toxic when dosed intravenously to animals according to the following guidelines. Animals expiring during the experimental protocol for reasons unrelated to the model should be necropsied and examined for opportunistic infections or other causes of premature death. Premature deaths, outside of injection-related adverse reactions, cannot be attributed to Clodrosome treatment alone.&lt;/div&gt;
&lt;ol style=&quot;border: 0px; list-style-image: initial; list-style-position: initial; margin: 0px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Plan the experimental setup and protocol keeping in mind that the animals receiving Clodrosome will become immune-suppressed within hours after treatment making sterile procedures for dosing and handling the animals more important than usual.&lt;ul style=&quot;background-color: transparent; border: 0px; list-style: disc; margin: 0px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;While full-blown immunocompromised animal containment is usually not necessary (depending on the size and potential for contamination in the facility), extra precautions need to be implemented, such as more frequently supplying clean bedding, water-bottles and food on a daily basis, as well as closely monitoring the animals for signs of infection or illness not related to the experimental model.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Take into account that Clodrosome-treated animals may succumb to infectious disease models at a higher rate than normal animals requiring shorter intervals for assessing the animals’ conditions.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;A significant number of unexpected deaths, outside of injection-related adverse reactions, should be investigated as it is likely due to opportunistic infections whose source must be eliminated from the facility environment or handling procedures.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Inflammation or necrosis at the injection site of only a few animals suggests contamination during the injection procedure while such reactions in several animals can be an indication that the clodronate liposome suspension has been contaminated. In this case the validity of the experiment should be seriously questioned.&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Generally, the maximum tolerable volume (ml) dosed to animals in a single, intravenous bolus should be limited to approximately 1% of the animal’s body weight in grams.&lt;ul style=&quot;background-color: transparent; border: 0px; list-style: disc; margin: 0px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;For example, the maximum volume dosed to a 20 g mouse is 0.2 ml. Many sources will cite more conservative guidelines of 5 ml/Kg (0.1 ml/20 g mouse) or a maximum 4-5% dilution of the total blood volume (TBV~1.2 ml/20 g mouse X 5% = 0.06 ml/mouse), however, if the technician is experienced in maintaining a slow, steady injection rate along with the other precautions listed here, the larger volume is well tolerated.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;In the event that the investigator suspects that injection-related adverse events are interfering with the study, Clodrosome can be diluted and dosed via intravenous infusion or smaller doses may be evaluated for effectiveness. However, this is rarely necessary.&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Clodrosome should be at RT for dosing to healthy animals; infected or otherwise compromised animals (i.e. SCID or nude mice) may require Clodrosome be warmed to the animal’s body temp prior to injection.&lt;ul style=&quot;background-color: transparent; border: 0px; list-style: disc; margin: 0px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Animals that are dosed intravenously with larger volumes of cold fluids can go into hypothermic shock.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Note that Clodrosome should be maintained at 4°C as much as possible. Consider making a sterile transfer of the total volume required for a single experiment from the original vial to another sterile container which can be warmed to the appropriate temperature, if the animal dosing protocol is expected to require Clodrosome to be maintained at elevated temperature for longer than an hour.&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Immediately before extracting Clodrosome from the vial, visually inspect the suspension, making sure that it is homogeneous with no visible particulates.&lt;ul style=&quot;background-color: transparent; border: 0px; list-style: disc; margin: 0px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Occasionally, liposomes will “settle” toward the bottom of the vial in which case the vial should be slowly and smoothly inverted several times.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Never vigorously shake liposomes; they will not “break”, but lipid-stabilized air bubbles can be introduced into the suspension. If these are transferred into the syringe and dosed to an animal, it could be seriously injured or killed by&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;air emboli&amp;nbsp;&lt;/strong&gt;(air bubbles introduced into the bloodstream).&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Also visually inspect Clodrosome once it is drawn into the syringe to ensure that no air bubbles have been introduced during its extraction from the vial. Following proper syringe-filling and air-bubble-removal procedures should prevent any incidents due to air emboli.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Some claim that air emboli are only an issue when introduced into arteries and that venous air emboli diffuse into the lungs when passing through the lung capillary bed, however many report adverse reactions when suspensions containing air bubbles are injected intravenously.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;It is probable that air-bubbles in the Clodrosome suspension are stabilized by a monolayer of lipid, and therefore may not be as readily dissolved as air bubbles in an aqueous solution. This is characteristic of liposome suspensions and does not indicate a quality issue with Clodrosome. However, if a substantial increase in bubbles or foam is noticed with older Clodrosome suspensions, it may be an indication of degraded lipid and the Clodrosome should not be used.&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;The other important reason for removing all air bubbles is that included&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;air bubbles occupy space in the needle and syringe&amp;nbsp;&lt;/strong&gt;so that the volume of suspension in the needle/syringe is less than the measured volume.&lt;ul style=&quot;background-color: transparent; border: 0px; list-style: disc; margin: 0px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Syringes are calibrated to deliver the indicated volume with the syringe tip and needle hub completely filled.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;It is not an issue when dosing Clodrosome directly from the vial, but the dead volume in a 1 ml syringe and needle hub is substantial (70 µl) compared to the 100-200 µl dose intended for mice. If this dead volume is not taken into account when using a single 1 ml syringe to draw up and/or dilute a suspension within the syringe, significant dosing errors can occur [11].&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;If necessary, a temporary&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;engorgement of the vein&amp;nbsp;&lt;/strong&gt;may make the injection easier.&lt;ul style=&quot;background-color: transparent; border: 0px; list-style: disc; margin: 0px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;For example, some technicians briefly dip the tail into warm—not HOT—water in order to make the vein more prominent; warm compresses may be applied to rabbit ears; tourniquets are appropriate for use on limbs in dogs.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Some technicians place animals under heat lamps, but this is discouraged, especially in small rodents, as the animals are often overheated leading to additional trauma and discomfort.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;If the vein is not easily visualized or accessed, consider using another injection route, such as retro-orbital injection as described above.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Remember that any change in protocol usually must be approved by the institutional animal care and use committee, therefore it is often useful to include alternative injection sites and/or methods in the initial application to the committee.&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Once the needle is inserted into the tail vein,&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;slowly and steadily inject the suspension at a rate of no more than 1 ml/minute.&amp;nbsp;&lt;/strong&gt;This translates to taking about 12-15 seconds to inject a 0.2 ml dose volume. Should the animal become overly agitated or begin gasping for air as discussed above, further decrease the injection rate. The slow injection rate allows the liposome suspension to be thoroughly mixed into the blood so that they are properly opsonized for optimal phagocyte uptake.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;The animals should be closely observed for a few minutes for adverse reactions after the injection is completed and the animal returned to the cage. The investigator should consider excluding animals from the study which demonstrate significant aberrant behavior.&lt;/li&gt;
&lt;/ol&gt;
&lt;div&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Margination of Circulating Monocytes.&amp;nbsp;&lt;/strong&gt;The entire population of monocytes (or neutrophils) within the vasculature at any given time is not represented in a blood sample.&amp;nbsp; Margination is the term used to describe the adhesion of monocytes, or other cells, to the vascular endothelium; margination occurs under both steady state and inflammatory conditions and precedes the extravasation of monocytes into the tissue where they mature into tissue macrophages or dendritic cells. A review of the mechanism and cell surface molecules involved in margination was published by Beekhuizen and van Furth [23]. Ohgami,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&amp;nbsp;&lt;/em&gt;reported that 5-7X more monocytes lined the vasculature of the lungs in rabbits than were found in the circulation while the number of marginated neutrophils was 2-3X that of the circulating neutrophil population [26]. These authors and others speculate that the margination is in preparation for replacing depleted alveolar macrophages. van Furth and Sluiter had previously reported a 60-40 distribution of marginated-circulating monocyte population in Swiss mice based on tail-vein blood collection rather than lungs and further speculate that the marginated and circulating monocytes exchange readily as has been shown for neutrophils [25].&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Although their focus was on the mechanism of granulocyte margination, Fehr and Jacob had already identified complement activation as at least one factor which induced margination of both monocytes and granulocytes in rabbits as well as humans receiving dialysis [24]. Given that liposomes are known to activate complement [27, 28], it is not surprising that Sunderkötter,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&amp;nbsp;&lt;/em&gt;showed that DiD-labeled liposomes (fluorescent clodronate liposome controls with no encapsulated clodronate) induced the margination of monocytes in mice which began to resolve somewhere between 4 and 16 hours post-injection [29]. However, these authors attribute the margination phenomenon to a cellular reaction upon phagocytosis of liposomes. Although the fact that the monocyte margination was more likely due to complement activation rather than phagocytotic events, we do not believe that the authors other conclusions would have been disputed by this realization.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
What is most important when reviewing the Sunderkötter,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&amp;nbsp;&lt;/em&gt;results is that apparent monocyte “depletion” at early time points (at least before 4 hours, but probably even longer) can be attributed to margination rather than actual monocyte death. Furthermore, as early as 2 hours post-liposome injection, new monocytes from the bone marrow began to appear in the bloodstream in these animals but not in clodronate liposome-treated mice, suggesting that the clodronate liposomes also depleted the immature monocytes in the bone marrow since clodronate liposomes would not have remained in the circulation for more than 2 hours. However, immature monocytes (Ly-6C&amp;nbsp;&lt;sup&gt;hi&amp;nbsp;&lt;/sup&gt;) began to reappear in the circulation sometime between 24 and 30 hours and reach baseline counts before 48 hours, although the steady-state distribution of Ly-6C&amp;nbsp;&lt;sup&gt;lo&amp;nbsp;&lt;/sup&gt;(mature) vs Ly-6C&amp;nbsp;&lt;sup&gt;hi&amp;nbsp;&lt;/sup&gt;(immature) monocytes was not re-established until somewhere between 4 and 7 days. The authors further discuss the differences between these monocyte subpopulations which should be considered when looking at circulating monocyte behavior before and after depletion.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Monocyte margination post-low-level-LPS challenge appeared to be responsible for acute lung injury according to O’Dea,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&amp;nbsp;&lt;/em&gt;[31] and that the margination elicited monocyte egress from the bone marrow. Lung injury correlated to the newly circulating monocytes preferentially marginating to the lung. Monocytes marginate to other organs in addition to the lungs during LPS-challenge and may contribute to sepsis-induced damage to these organs as well.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
It is not clear to us whether or not marginated macrophages phagocytose clodronate liposomes in normal animals, but Bouwens and Wisse reported marginated monocyte uptake of latex particles in a model in which margination of monocytes in the liver was accomplished by Zymosan-(particles prepared from yeast membranes)induced inflammation [32]. Therefore, we might assume that marginated monocytes will be depleted in models where inflammation exists at the time of clodronate liposome administration. Clearly, the status and contribution of marginated monocytes requires additional investigation.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
Some report that any increased stress in such as restraint during the act of collecting a blood sample can affect the number of circulating monocytes.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;RES blockade&amp;nbsp;&lt;/strong&gt;is the result of the saturation of blood-accessible phagocytic cells such that circulating liposomes or other particles are not removed from the bloodstream [34]. There is also evidence that depletion of blood-borne opsonins may contribute to the hampered particle uptake [28]. Liposomes, latex beads, Zymosan are examples of particles which effectively induce RES blockade. Phagocytes can digest liposomes within a day so that the blockade is reversible, however latex cannot be metabolized and the phagocyte seems to retain some level of impairment until it is replaced after its normal lifespan. Therefore, it does make a difference as to which agent is used to accomplish the blockade. The application of RES blockade is discussed in detail on the Mannosylated Liposomes page under&amp;nbsp;&lt;a href=&quot;http://www.clodrosome.com/other-info/mannosylated-liposomes/#&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot;&gt;A Strategy for Targeting Phagocytes Resistant to Clodronate Liposome Depletion.&lt;/a&gt;&amp;nbsp;RES blockade may be induced by dosing the particles either through the vascular or the peritoneal route, however vascular dosing is somewhat more efficient.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Rates of Macrophage Repopulation.&amp;nbsp;&lt;/strong&gt;The steady state distribution of macrophage subpopulations may not be represented during repopulation post-depletion as discussed earlier for monocytes. Therefore, if a study involves the behavior of a phagocyte class during the repopulation phase, those results may not be reflective of the steady state behavior of those cells. However, the most confounding issue for many is the fact that monocyte repopulation may begin as early as 24 hours while spleen and liver macrophage depletion can last as long as 7 days. Therefore, if complete systemic macrophage depletion or just monocyte depletion is the goal, daily injections of clodronate liposomes may be necessary for experimental protocols requiring data collection more than 1 day post injection of the clodronate liposomes. Also take into account that the results on monocyte repopulation reported above were obtained in mice and other species may demonstrate different repopulation kinetics as has been shown for splenic macrophage repopulation between mice and rats.&lt;/div&gt;
&lt;div style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;In conclusion,&lt;/strong&gt;&amp;nbsp;intravenous administration is the most commonly used method for dosing clodronate liposomes, however many factors still need to be taken into account to ensure that the depletion provides the required results. Phagocyte depletion should always be verified in the tissue(s) of interest and results cannot be extrapolated from species to species. Even amongst mice of the same strain, knockouts or other genetically altered animals may have resulting traits which could alter their response to clodronate liposomes. Thus careful consideration of the effect of clodronate liposomes through a thorough understanding of their expected behavior post-intravenous injection must accompany every study. Developing the skills for designing the appropriate experiments and controls to explain unexpected results as well as achieve the desired results must also be integrated into the use of clodronate liposomes for phagocyte depletion.&lt;/div&gt;
&lt;div style=&quot;border: 0px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;/div&gt;
&lt;hr style=&quot;border-bottom-width: 0px; border-color: rgb(204, 204, 204); border-left-width: 0px; border-right-width: 0px; border-style: solid; clear: both; color: #050505; font-family: Arial; font-size: 14px; height: 0px; line-height: 23px; margin-bottom: 20px;&quot; /&gt;
&lt;h5 style=&quot;border: 0px; color: #373738; font-family: Arial; font-size: 1.5em !important; font-weight: normal; line-height: 1.2em; margin: 15px 0px 2px; outline: 0px; padding: 0px 0px 2px; vertical-align: baseline;&quot;&gt;
References&lt;/h5&gt;
&lt;hr style=&quot;border-bottom-width: 0px; border-color: rgb(204, 204, 204); border-left-width: 0px; border-right-width: 0px; border-style: solid; clear: both; color: #050505; font-family: Arial; font-size: 14px; height: 0px; line-height: 23px; margin-bottom: 20px;&quot; /&gt;
&lt;ol style=&quot;border: 0px; list-style-image: initial; list-style-position: initial; margin: 0px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Fenestrated capillaries also exist in the glomeruli of the kidneys, however the glomerular structure includes architecture which reduces the effective size of the pores to 20-30 nm so that serum proteins (i.e. albumin) are not excreted. Therefore liposomes cannot pass through these fenestrae. See Patrakka J, Tryggvason K.&amp;nbsp;&lt;a href=&quot;http://linkinghub.elsevier.com/retrieve/pii/S0006291X10007382&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Molecular make-up of the glomerular filtration barrier.&amp;nbsp;&lt;/a&gt;Biochemical and Biophysical Research Communications. 2010 May;396(1):164–9.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Sou K, Goins B, Oyajobi BO, Travi BL, Phillips WT.&amp;nbsp;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076608/&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Bone marrow-targeted liposomal carriers.&amp;nbsp;&lt;/a&gt;Expert Opin Drug Deliv. 2011 Mar;8(3):317–28.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Moghimi SM.&amp;nbsp;&lt;a href=&quot;http://www.sciencedirect.com/science/article/pii/0169409X95000415&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Exploiting bone marrow microvascular structure for drug delivery and future therapies.&amp;nbsp;&lt;/a&gt;Advanced Drug Delivery Reviews. 1995 Oct;17(1):61–73.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Luk SC, Simon GT.&amp;nbsp;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1910940/&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Phagocytosis of Colloidal Carbon and Heterologous Red Blood Cells in the Bone Marrow of Rats and Rabbits.&amp;nbsp;&lt;/a&gt;Am J Pathol. 1974 Dec;77(3):423–38.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;&lt;a href=&quot;http://http//www.research.psu.edu/arp/training/videos/retroorbital-injections-in-the-mouse&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Retro-orbital Injection in the Mouse — Penn State University [Internet].&amp;nbsp;&lt;/a&gt;[cited 2012 Jul 3]. Available from: http://www.research.psu.edu/arp/training/videos/retroorbital-injections-in-the-mouse&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Yardeni T, Eckhaus M, Morris HD, Huizing M, Hoogstraten-Miller S.&amp;nbsp;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3158461/&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Retro-orbital injections in mice.&amp;nbsp;&lt;/a&gt;Lab Anim (NY). 2011 May;40(5):155–60.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Kim C, Kim I, Kim S, Kim Y, Kang S, Moon S, et al.&amp;nbsp;&lt;a href=&quot;http://www.springerlink.com/content/20q7t7601001h246/abstract/&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Comparison of the Intraperitoneal, Retroorbital and per Oral Routes for F-18 FDG Administration as Effective Alternatives to Intravenous Administration in Mouse Tumor Models Using Small Animal PET/CT Studies.&amp;nbsp;&lt;/a&gt;Nuclear Medicine and Molecular Imaging. 2011;45(3):169–76.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Nanni C, Pettinato C, Ambrosini V, Spinelli A, Trespidi S, Rubello D, et al.&amp;nbsp;&lt;a href=&quot;http://journals.lww.com/nuclearmedicinecomm/Abstract/2007/07000/Retro_orbital_injection_is_an_effective_route_for.6.aspx&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies.&amp;nbsp;&lt;/a&gt;Nuclear Medicine Communications. 2007 Jul;28(7):547–53.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Calin MV, Manduteanu I, Dragomir E, Dragan E, Nicolae M, Gan AM, et al.&amp;nbsp;&lt;a href=&quot;http://www.springerlink.com/index/10.1007/s00441-009-0765-2&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Effect of depletion of monocytes/macrophages on early aortic valve lesion in experimental hyperlipidemia.&amp;nbsp;&lt;/a&gt;Cell and Tissue Research. 2009 Mar 20;336(2):237–48.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Winkler IG, Sims NA, Pettit AR, Barbier V, Nowlan B, Helwani F, et al.&amp;nbsp;&lt;a href=&quot;http://www.bloodjournal.org/cgi/doi/10.1182/blood-2009-11-253534&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs.&amp;nbsp;&lt;/a&gt;Blood. 2010 Aug 16;116(23):4815–28.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Bhambhani V, Beri R, Puliyel J.&amp;nbsp;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1721932/&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Inadvertent overdosing of neonates as a result of the dead space of the syringe hub and needle.&amp;nbsp;&lt;/a&gt;Arch Dis Child Fetal Neonatal Ed. 2005 Sep;90(5):F444–F445.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Afergan E, Epstein H, Dahan R, Koroukhov N, Rohekar K, Danenberg HD, et al.&amp;nbsp;&lt;a href=&quot;http://linkinghub.elsevier.com/retrieve/pii/S016836590800494X&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes.&amp;nbsp;&lt;/a&gt;Journal of Controlled Release. 2008 Dec;132(2):84–90.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Qian Q, Jutila MA, Van Rooijen N, Cutler JE.&amp;nbsp;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/8176217&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis.&amp;nbsp;&lt;/a&gt;J. Immunol. 1994 May 15;152(10):5000–8.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Winkler IG, Sims NA, Pettit AR, Barbier V, Nowlan B, Helwani F, et al.&amp;nbsp;&lt;a href=&quot;http://www.bloodjournal.org/cgi/doi/10.1182/blood-2009-11-253534&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs.&amp;nbsp;&lt;/a&gt;Blood. 2010 Aug 16;116(23):4815–28.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Alexander KA, Chang MK, Maylin ER, Kohler T, Müller R, Wu AC, et al.&amp;nbsp;&lt;a href=&quot;http://doi.wiley.com/10.1002/jbmr.354&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model.&amp;nbsp;&lt;/a&gt;Journal of Bone and Mineral Research. 2011 Jul;26(7):1517–32.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Chow A, Lucas D, Hidalgo A, Méndez-Ferrer S, Hashimoto D, Scheiermann C, et al.&amp;nbsp;&lt;a href=&quot;http://jem.rupress.org/content/208/2/261&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche.&amp;nbsp;&lt;/a&gt;J Exp Med. 2011 Feb 14;208(2):261–71.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Lévesque J-P, Helwani FM, Winkler IG.&amp;nbsp;&lt;a href=&quot;http://www.nature.com/leu/journal/v24/n12/full/leu2010214a.html&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;The endosteal “osteoblastic” niche and its role in hematopoietic stem cell homing and mobilization.&lt;/a&gt;Leukemia. 2010;24(12):1979–92.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Brown JM, Giaccia AJ.&amp;nbsp;&lt;a href=&quot;http://cancerres.aacrjournals.org/content/58/7/1408&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;The Unique Physiology of Solid Tumors: Opportunities (and Problems) for Cancer Therapy.&amp;nbsp;&lt;/a&gt;Cancer Res. 1998 Apr 1;58(7):1408–16.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Kopp H-G, Avecilla ST, Hooper AT, Rafii S.&amp;nbsp;&lt;a href=&quot;http://physiologyonline.physiology.org/content/20/5/349&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;The Bone Marrow Vascular Niche: Home of HSC Differentiation and Mobilization.&amp;nbsp;&lt;/a&gt;Physiology. 2005 Oct 1;20(5):349–56.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Lin JH.&amp;nbsp;&lt;a href=&quot;http://www.sciencedirect.com/science/article/pii/8756328295004459&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Bisphosphonates: A review of their pharmacokinetic properties.&amp;nbsp;&lt;/a&gt;Bone. 1996 Feb;18(2):75–85.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Kellinsalmi M, Mönkkönen H, Mönkkönen J, Leskelä H-V, Parikka V, Hämäläinen M, et al.&amp;nbsp;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/16364054&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.&amp;nbsp;&lt;/a&gt;Basic Clin. Pharmacol. Toxicol. 2005 Dec;97(6):382–91.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Makkonen N, Salminen A, Rogers MJ, Frith JC, Urtti A, Azhayeva E, et al.&amp;nbsp;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/10210733&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite.&amp;nbsp;&lt;/a&gt;Eur J Pharm Sci. 1999 May;8(2):109–18.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Beekhuizen H, van Furth R.&amp;nbsp;&lt;a href=&quot;http://www.jleukbio.org/content/54/4/363&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Monocyte adherence to human vascular endothelium.&amp;nbsp;&lt;/a&gt;J Leukoc Biol. 1993 Oct 1;54(4):363–78.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Fehr J, Jacob HS.&amp;nbsp;&lt;a href=&quot;http://jem.rupress.org/content/146/3/641&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;In vitro granulocyte adherence and in vivo margination: two associated complement-dependent functions.&amp;nbsp;&lt;/a&gt;J Exp Med. 1977 Sep 1;146(3):641–52.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;van Furth R, Sluiter W.&amp;nbsp;&lt;a href=&quot;http://jem.rupress.org/content/163/2/474&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Distribution of blood monocytes between a marginating and a circulating pool.&amp;nbsp;&lt;/a&gt;J Exp Med. 1986 Feb 1;163(2):474–9.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Ohgami M, Doerschuk CM, Gie RP, English D, Hogg JC.&amp;nbsp;&lt;a href=&quot;http://jap.physiology.org/content/70/1/152&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Monocyte kinetics in rabbits.&amp;nbsp;&lt;/a&gt;J Appl Physiol. 1991 Jan 1;70(1):152–7.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Szebeni J.&amp;nbsp;&lt;a href=&quot;http://dl.begellhouse.com/journals/3667c4ae6e8fd136,36d0b6b2180d2635,7b8320963dd80886.html&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;The Interaction of Liposomes with the Complement System.&amp;nbsp;&lt;/a&gt;Critical Reviews&amp;nbsp;&lt;sup&gt;TM&amp;nbsp;&lt;/sup&gt;in Therapeutic Drug Carrier Systems. 1998;15(1):57-88.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Semple S, Chonn A, Cullis PR.&amp;nbsp;&lt;a href=&quot;http://linkinghub.elsevier.com/retrieve/pii/S0169409X97001282&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo.&amp;nbsp;&lt;/a&gt;Advanced Drug Delivery Reviews. 1998 Jun;32(1-2):3–17.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Sunderkötter C, Nikolic T, Dillon MJ, van Rooijen N, Stehling M, Drevets DA, et al.&amp;nbsp;&lt;a href=&quot;http://www.jimmunol.org/content/172/7/4410&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Subpopulations of Mouse Blood Monocytes Differ in Maturation Stage and Inflammatory Response.&amp;nbsp;&lt;/a&gt;J Immunol. 2004 Apr 1;172(7):4410–7.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;van Rooijen N, Kors N, Kraal G.&amp;nbsp;&lt;a href=&quot;http://www.jleukbio.org/content/45/2/97.abstract&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Macrophage subset repopulation in the spleen: differential kinetics after liposome-mediated elimination.&lt;/a&gt;Journal of Leukocyte Biology. 1989 Feb 1;45(2):97 –104.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;O’Dea KP, Wilson MR, Dokpesi JO, Wakabayashi K, Tatton L, van Rooijen N, et al.&amp;nbsp;&lt;a href=&quot;http://www.jimmunol.org/content/182/2/1155.long&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Mobilization and margination of bone marrow Gr-1high monocytes during subclinical endotoxemia predisposes the lungs toward acute injury.&amp;nbsp;&lt;/a&gt;The Journal of Immunology. 2009;182(2):1155.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;O’Dea KP, Young AJ, Yamamoto H, Robotham JL, Brennan FM, Takata M.&amp;nbsp;&lt;a href=&quot;http://ajrccm.atsjournals.org/content/172/9/1119&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Lung-marginated Monocytes Modulate Pulmonary Microvascular Injury during Early Endotoxemia.&amp;nbsp;&lt;/a&gt;Am. J. Respir. Crit. Care Med. 2005 Nov 1;172(9):1119–27.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Bouwens L, Wisse E.&amp;nbsp;&lt;a href=&quot;http://www.jleukbio.org/content/37/5/531&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Proliferation, kinetics, and fate of monocytes in rat liver during a zymosan-induced inflammation.&amp;nbsp;&lt;/a&gt;J Leukoc Biol. 1985 May 1;37(5):531–43.&lt;/li&gt;
&lt;li style=&quot;background-color: transparent; border: 0px; margin: 0px 0px 0px 30px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;&lt;div style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;div style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;div style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
Proffitt RT, Williams LE, Presant CA, Tin GW, Uliana JA, Gamble RC, et al.&amp;nbsp;&lt;a href=&quot;http://www.sciencemag.org/content/220/4596/502&quot; style=&quot;background-color: transparent; border: 0px; color: #002dcf; margin: 0px; outline: 0px; padding: 0px; text-decoration: initial; vertical-align: baseline;&quot; target=&quot;_blank&quot;&gt;Liposomal Blockade of the Reticuloendothelial System: Improved Tumor Imaging with Small Unilamellar Vesicles.&lt;/a&gt;&amp;nbsp;Science. 1983 Apr 29;220(4596):502–5.&lt;/div&gt;
&lt;div style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
For the original website, see here:&lt;/div&gt;
&lt;div style=&quot;background-color: transparent; border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;span style=&quot;color: #050505; font-family: Arial;&quot;&gt;&lt;span style=&quot;font-size: 14px; line-height: 23px;&quot;&gt;&lt;a href=&quot;http://www.clodrosome.com/routes-of-administration/intravenous/&quot;&gt;http://www.clodrosome.com/routes-of-administration/intravenous/&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/li&gt;
&lt;/ol&gt;
&lt;/div&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;/200&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;ol style=&quot;border: 0px; color: #050505; font-family: Arial; font-size: 14px; line-height: 23px; list-style-image: initial; list-style-position: initial; margin: 0px 0px 2px; outline: 0px; padding: 0px; text-align: -webkit-auto; vertical-align: baseline;&quot;&gt;
&lt;/ol&gt;
&lt;/div&gt;
</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/6571878629028507289'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/6571878629028507289'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2012/07/systemic-administration-of-clodronate.html' title='Systemic Administration of Clodronate Liposomes via Intravenous (IV) Injection'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhhosfbV2-Qpn25tpARiQ2HgPycGjht6UHHMatAHPvQ7q7kKWVdvL3DlHEbfRfZZrs4_xUiANVb3DRIIl4rq1m-pqvUtgEctKwg1kzqvTQKVQwix2ornNMOAoMnblW_qsHNNdRoZNrhe2c/s72-c/Liver-Sinusoid.png" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-7428332359898817197</id><published>2012-05-31T15:58:00.002-05:00</published><updated>2012-07-09T19:28:08.120-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodrosome"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposome"/><category scheme="http://www.blogger.com/atom/ns#" term="mannosylated liposomes"/><title type='text'>Mannosylated Liposomes</title><content type='html'>&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;span style=&quot;font-family: inherit;&quot;&gt;&lt;span style=&quot;background-color: white; color: #050505; line-height: 23px; text-align: left;&quot;&gt;We are continuing to review publications related to mannosylated liposomes. This discussion will be updated with any pertinent information as we find it or whenever new information is published.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;span style=&quot;font-family: inherit;&quot;&gt;&lt;span style=&quot;background-color: white; color: #050505; line-height: 23px; text-align: left;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;span style=&quot;background-color: white; color: #050505; font-family: inherit; line-height: 23px; text-align: left;&quot;&gt;&lt;b&gt;Summary&lt;/b&gt;&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;span style=&quot;font-family: inherit;&quot;&gt;&lt;span style=&quot;background-color: white; color: #050505; line-height: 23px;&quot;&gt;Mannose receptor binding is one of the oldest proposed mechanisms for liposome targeting through surface modification of the liposomes. The increasing number of both cell-surface-associated and soluble mannose-binding proteins that have since been discovered reveal the complexity of the mechanism(s) involved in enhanced uptake of mannosylated liposomes [1]. Yet, several publications present convincing data on the ability of liposomes with various different conformations of surface bound mannose molecules to target mannose-receptor positive cells both&amp;nbsp;&lt;/span&gt;&lt;em style=&quot;background-color: white; border: 0px; color: #050505; line-height: 23px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;in vitro&amp;nbsp;&lt;/em&gt;&lt;span style=&quot;background-color: white; color: #050505; line-height: 23px;&quot;&gt;and&amp;nbsp;&lt;/span&gt;&lt;em style=&quot;background-color: white; border: 0px; color: #050505; line-height: 23px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;in vivo.&amp;nbsp;&lt;/em&gt;&lt;span style=&quot;background-color: white; color: #050505; line-height: 23px;&quot;&gt;Unfortunately, most of these proven formulations have not been applied to selective macrophage depletion by encapsulation of clodronate in these liposomes. The clodronate liposome field, in particular, has been plagued by the introduction of a liposome formulation prepared in the presence of p-aminophenyl mannose, but without covalently coupling this modified sugar to the liposome surface. The profusely cited reference to this liposome preparation claimed to target mannose-receptor positive cells in the brain as well as deliver liposome cargo across the blood-brain barrier. We find the data in this paper to be very weak and cannot confirm that the formulation was ever appropriately characterized with respect to the presence of mannose capable of targeting the liposome to mannose-binding proteins. While some stronger data suggesting that this formulation may target mannose-receptor positive cells has been published, others find no evidence of targeting by this formulation. We conclude that studies specifically designed to characterize and assess the targeting ability of this formulation are required to justify the use of this formulation in targeting mannose-receptor positive phagocytes. Until these studies are completed and published, we recommend that formulations containing covalently-anchored mannose and demonstrating the ability to selectively bind mannose receptors be utilized when experimental design calls for mannose receptor targeting.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;span style=&quot;background-color: white; color: #050505; font-family: inherit; line-height: 23px; text-align: justify;&quot;&gt;Many different mannosylated lipids have been synthesized which effectively display mannose residues on the surface of liposomes suitable for binding to mannose receptors as judged by Con A agglutination and competitive inhibition of mannose receptor binding by mannose or mannose-containing macromolecules. These demonstrations, however, are more difficult to interpret&amp;nbsp;&lt;/span&gt;&lt;em style=&quot;border: 0px; color: #050505; font-family: inherit; line-height: 23px; margin: 0px; outline: 0px; padding: 0px; text-align: justify; vertical-align: baseline;&quot;&gt;in vivo&lt;/em&gt;&lt;span style=&quot;background-color: white; color: #050505; font-family: inherit; line-height: 23px; text-align: justify;&quot;&gt;because of the multiple mechanisms by which phagocyte uptake of mannosylated liposomes is enhanced. The structures of these mannosylated lipids are shown on this page along with a brief discussion of the published characterization and behavior of liposomes containing these derivatives. While the rationale for the design, synthesis and biophysical properties of these molecules may not seem directly applicable to clodronate liposome studies, there is a great deal of useful information in these papers on the rational design of surface-modified liposomes which will be invaluable when interpreting mannosylated clodronate liposome depletion data as well as when attempting to deplete specific mannose-receptor-positive phagocyte subsets.&lt;/span&gt;&lt;br /&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; text-align: left; vertical-align: baseline;&quot;&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;span style=&quot;font-family: inherit;&quot;&gt;Despite the large number of publications by those attempting to deplete mannose-receptor-positive phagocyte populations with liposomal clodronate prepared in the presence of p-aminophenyl mannose, combined with as many, or more, papers from those designing mannosylated liposomes for targeting cells displaying macrophage receptors, thus far, we have found only one paper describing mannosylated clodronate liposomes that were confirmed to target mannose receptors&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;in vitro.&lt;/em&gt;&amp;nbsp;Therefore, there is a great deal of work to be done with regard to evaluating the use and advantages of mannosylated clodronate liposomes.&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style=&quot;background-color: white; border: 0px; color: #050505; line-height: 23px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; text-align: left; vertical-align: baseline;&quot;&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;span style=&quot;font-family: inherit;&quot;&gt;We are awaiting publication of data from one group to whom we supplied covalently-coupled mannosylated liposomes; they have indicated achieving successful targeting and depletion of a mannose-receptor positive phagocyte subpopulation. By compiling the information on this page, it is our intention to equip everyone with the basic tools necessary for successful, unequivocal mannose receptor targeting using mannosylated clodronate liposomes.&amp;nbsp;&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style=&quot;border: 0px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;span style=&quot;font-family: inherit;&quot;&gt;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Introduction.&lt;/strong&gt;&amp;nbsp;Multiple studies have shown that modifying the surface of liposomes with&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;mannose&lt;/strong&gt;&amp;nbsp;[1] increases the uptake of these liposomes in phagocytes bearing a mannose receptor mechanism [2, 3, 4, 15] as far back as the mid-1970′s [8]. Obviously, this is not a new idea although Juliano’s first efforts actually produced a liposome with the&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;lectin (carbohydrate-binding protein)&lt;/strong&gt;&amp;nbsp;on the surface rather than the sugar. While we are focusing on mannosylation, many other publications describe liposome targeting using other carbohydrates. The significant amount of data on mannose and other carbohydrate targeting should not be confused with being able to selectively target macrophage subpopulations which may express mannose receptors. Mannosylated-liposome uptake is enhanced by other mechanisms unrelated to mannose receptor binding, such as recognition by&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;mannose-binding protein (MBP or MBL)&lt;/strong&gt;&amp;nbsp;, which activates complement and initiates uptake by complement receptor mediated phagocytosis [5, 11]. While all liposomes activate complement and bind other serum opsonins to some extent, certain types of liposomes (i.e. 100 nm DSPC/cholesterol liposomes) bind much less complement than others, thus exhibit extended circulation times post-i.v. injection&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;in vivo.&lt;/em&gt;However, when mannose or other carbohydrates were covalently attached to the liposome surfaces, they are rapidly cleared from the bloodstream [6]. This has even been shown for so-called “stealth” liposomes, known for their ability to avoid immediate phagocyte uptake [71].&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style=&quot;border: 0px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;span style=&quot;font-family: inherit;&quot;&gt;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Why Mannose?&amp;nbsp;&lt;/strong&gt;Mannose is one of the carbohydrate components of many bacterial and viral cell surfaces, therefore the ever-efficient, highly redundant immune system has evolved multiple mechanisms for identifying pathogens based on mannose recognition. The animal and plant kingdoms likewise utilize carbohydrate recognition signalling mechanisms including mannose residues. Many publications evaluate other carbohydrates as targeting mechanisms for various cell types, however mannose targeting to phagocytes appears to be one of the more specific mechanisms identified to date [6]. Mammalian cell surface identification molecules based on mannose binding, such as the ICAM family of leukocyte adhesion molecules,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;&lt;/em&gt;target the SIGN family of mannose receptors to accomplish self-recognition&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;in vivo&amp;nbsp;&lt;/em&gt;[12, 13, 14]. Several other mannose-binding molecules have been identified, but not all of them have been connected to their biologically relevant ligands and functions [3]. There are also a large bodies of work focusing on using mannosylated liposomes as an adjuvant, for non-specific immunostimulation and for nucleic acid delivery, the mechanisms all of which are somewhat outside the focus of this discussion [15, 16, 17, 18, 19]. However, these applications have provided a multitude of methods for synthesizing mannosylated-lipid conjugates that can be included into mannosylated-liposomal clodronate formulations.&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style=&quot;border: 0px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;span style=&quot;font-family: inherit;&quot;&gt;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Mannose- and Mannose-Liposome-Binding Serum Components.&lt;/strong&gt;&amp;nbsp;The abundance of both cell associated and soluble mannose receptors in serum contributes to the lack of specificity of mannose targeting [9]. As mentioned earlier, mannose-binding protein, present in mammalian serum, is very effective at complement activation when MBP is bound to mannose. Several studies describe the&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;soluble mannose receptor (sMR)&lt;/strong&gt;which is the extracellular portion of the&amp;nbsp; macrophage mannose receptor (MR) released by macrophages for transferring macrophage-processed antigens to antigen-presenting cells (&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Antigen Presenting Cell&quot;&gt;APC&lt;/acronym&gt;) [20]. While MBP requires the association of several subunits, each possessing a single carbohydrate binding domain (CRD) for high affinity binding, sMR possesses 8 CRDs on a single molecule. Therefore sMR has no requirement for self-association in serum before binding occurs as does MBP.&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style=&quot;border: 0px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;span style=&quot;font-family: inherit;&quot;&gt;MBP is closely related to&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;surfactant proteins A and D (SP-A, SP-D)&lt;/strong&gt;&amp;nbsp;which also bind mannose in the lung. Therefore, intrapulmonary administration of mannosylated liposomes will also result in binding of mannose-specific proteins that will compete with MR+ alveolar macrophages and other MR+ pulmonary phagocytes for the mannose on the liposome surface [22]. The receptors and functions of SP-A and SP-D have been the subject of conflicting reports and are still not clearly understood [91], furthermore these soluble mannose receptors are found in several locations outside the lung [92] making it somewhat more difficult to take into account how these lectins will affect mannosylated liposomes.&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style=&quot;border: 0px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;span style=&quot;font-family: inherit;&quot;&gt;Complement component,&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;C3&lt;/strong&gt;&amp;nbsp;, has been shown to covalently bind mannose during its activated state, although this has not been demonstrated&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;in vivo&lt;/em&gt;&amp;nbsp;[21].&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Antibodies&lt;/strong&gt;&amp;nbsp;bind both specifically (anti-phospholipid antibodies) and non-specifically to liposomes&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;in vivo&lt;/em&gt;&amp;nbsp;[7]. While not directly addressed in any of these publications, it seems that antibodies generated from previous exposure to various mannose-displaying pathogens may recognize some mannosylated liposomes due to their similar surface properties. We highlight these soluble mannose receptors, because when designing a targeted liposome, as with any other liposome for use&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;in vivo,&lt;/em&gt;&amp;nbsp;the first consideration is how the liposome will interact with the biological milieu before it reaches its potential target cell.&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style=&quot;border: 0px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;span style=&quot;font-family: inherit;&quot;&gt;In summary, the propensity for serum components binding to liposomes is enhanced by the presence of both mannose-specific and non-specific components when the liposomes are surface-modified by mannose. Most of this enhanced binding correlates to enhanced uptake of liposomes in the liver since removing foreign particles from the bloodstream is one of the liver’s primary functions. In fact, Ghosh,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&lt;/em&gt;&amp;nbsp;and other groups have demonstrated that mannosylated liposomes are preferentially phagocytosed by non-parenchymal liver cells, including Kupffer cells, while galactosylated liposomes tend to be associated with hepatocytes [41].&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style=&quot;border: 0px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;span style=&quot;font-family: inherit;&quot;&gt;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Cell-Surface Mannose Receptors.&lt;/strong&gt;&amp;nbsp;When developing a mannose-targeting rationale, the&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;macrophage mannose receptor (formerly MMR, now MR or CD206)&lt;/strong&gt;&amp;nbsp;is usually the targeting goal. This receptor was originally discovered and characterized from macrophages, but this receptor has since been found on dendritic cells, certain endothelial cells and as a non-cell-bound soluble form which has been shown to migrate from macrophages to antigen-presenting cells (&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Antigen Presenting Cell&quot;&gt;APC&lt;/acronym&gt;) as discussed above&amp;nbsp;[43, 44]. A structurally and functionally similar receptor,&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Endo-180&lt;/strong&gt;, was first identified on fibroblasts, but has now been identified on macrophages and endothelial cells in all tissues. Endo-180 appears to function in regulation of extracellular matrix catabolism and structuring.&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;DEC-205&lt;/strong&gt;, a mannose receptor first identified in maturing dendritic cells and one of the receptors which binds the soluble from of phospholipase A2,&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;M-PLA&lt;sub&gt;2&lt;/sub&gt;R&lt;/strong&gt;, also specifically binds mannose-containing molecules.&amp;nbsp; This family of cell surface mannose receptors all operate by the clathrin-mediated (coated-pit) endocytic mechanism which would limit the size of the liposome that could be internalized to a few hundred microns. However, MR itself is unique in that it also initiates actin-mediated phagocytosis although some speculate that MR requires cooperation with other receptors to accomplish phagocytosis. DEC-205 and M-PLA&lt;sub&gt;2&lt;/sub&gt;R are not likely to play a significant role in mannosylated liposome targeting, but their ability to bind specific mannose-containing molecules may recruit mannosylated liposomes to the cell surface increasing the likelihood that the liposome will come into contact with the phagocytic mannose-receptors.&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style=&quot;border: 0px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;span style=&quot;font-family: inherit;&quot;&gt;In addition to MR and Fc (antibody) receptors which allow dendritic cells to phagocytose pathogens, a distinctly different receptor which recognized mannose was first identified on these cells. This receptor was found to mediate the interaction between dendritic cells and T cells which allows the transfer of antigenic peptides produced by dendritic cells (from ingested pathogens) to the T cells (for antibody production) through the membrane-associated MHC shuttle. The receptor ligand on T cells was identified as ICAM-3 and the receptor was designated&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;&lt;acronym style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot; title=&quot;Dendritic Cell&quot;&gt;DC&lt;/acronym&gt;-SIGN&amp;nbsp;&lt;/strong&gt;as it had only been identified on dendritic cells [13, 14]. Of course, related receptors (&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;SIGNRs&lt;/strong&gt;) were later identified in many tissues including splenic red pulp and peritoneal macrophages (&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;SIGNR1&lt;/strong&gt;). Mannosylated-liposome targeting to this receptor demonstrates the requirement for complement receptor (CR3) participation in the phagocytosis of the liposomes suggesting that SIGN receptors do require cooperative support from other phagocytic receptors as has been speculated for MR [12].&amp;nbsp;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Langerin&lt;/strong&gt;&amp;nbsp;is another SIGN-like mannose-binding receptor speculated to be a target for mannosylated liposomes.&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style=&quot;border: 0px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;span style=&quot;font-family: inherit;&quot;&gt;Clearly, a variety of potential mannose-targeting sites exist on the surface of many cell types including those susceptible to depletion by liposomal clodronate. Although all of these sites may not initiate phagocytosis of clodronate liposomes, mannosylated clodronate liposomes may bind to any of these sites ensuring that the liposomes are in close proximity to cell-surface phagocytic receptors thus increasing the probability of liposome phagocytosis.&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style=&quot;border: 0px; margin-bottom: 5px; outline: 0px; padding: 5px 0px; vertical-align: baseline;&quot;&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;span style=&quot;font-family: inherit;&quot;&gt;&lt;strong style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;Is there a Rationale for using Mannosylated Clodronate Liposomes?&lt;/strong&gt;&amp;nbsp;Given that mannosylated liposomes are expected to demonstrate enhanced uptake by all (not only those with mannose receptors) accessible phagocytic cells&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;&lt;/em&gt;due to their increased level of opsonization, it is difficult to predict if the pattern of macrophage depletion will be substantially different&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;in vivo.&lt;/em&gt;&amp;nbsp;Buiting,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&lt;/em&gt;&amp;nbsp;report no significant differences in the biodistribution of clodronate liposomes of differing lipid compositions including the p-aminophenyl mannose formulation as well as a colvalently linked mannosyl-DOPE conjugate [48]. With regard to the covalently attached mannose liposomes, DOPE is a non-bilayer forming lipid which is known to be disruptive to liposomes under many conditions and is suspected to have demonstrated similar disruptive behavior as described for Weissig,&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;et. al.&lt;/em&gt;&amp;nbsp;below. Successful targeting with the PE-linked mannose studies employ DPPE or other bilayer-preferring PE species. Additionally, this mannosyl-DOPE conjugate does not include a flexible spacer which extends the mannose away from the liposome surface, the importance of which is also discussed below. Furthermore, most mannosylated-lipid studies report that two or more mannose residues per lipid are required for optimal mannose-receptor binding while this conjugate has a single mannose molecule per lipid. Taken all together, we believe that this covalently-linked mannose liposome formulation was not optimized for successful targeting. Yet, many mannose-conjugated lipid derivatives (shown below) do demonstrate selective uptake&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;in vitro&lt;/em&gt;&amp;nbsp;and different biodistribution patterns&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;in vivo&lt;/em&gt;, and there is a study showing that mannosylated (ManDog) clodronate liposomes are effective for depleting immature dentritic cells&amp;nbsp;&lt;em style=&quot;background-color: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;in vitro&lt;/em&gt;, while non-manosylated liposomes have no effect as discussed in detail below. These data suggest that depleting atypical subsets of phagocytes with well-characterized mannosylated clodronate liposomes is an intriguing possibility worth investigating.&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;br /&gt;
For the complete post see here:&amp;nbsp;&lt;a href=&quot;http://www.clodrosome.com/other-info/mannosylated-liposomes/&quot;&gt;http://www.clodrosome.com/other-info/mannosylated-liposomes/&lt;/a&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/7428332359898817197'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/7428332359898817197'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2012/05/mannosylated-liposomes-part-1.html' title='Mannosylated Liposomes'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-9084811576065914289</id><published>2012-05-29T11:33:00.003-05:00</published><updated>2012-05-29T11:36:26.988-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="100 nm"/><category scheme="http://www.blogger.com/atom/ns#" term="Fluorescent liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Fluoroliposome"/><category scheme="http://www.blogger.com/atom/ns#" term="lamellarity"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposome"/><category scheme="http://www.blogger.com/atom/ns#" term="osmolality"/><category scheme="http://www.blogger.com/atom/ns#" term="size"/><title type='text'>Liposomes and osmolality of the solution</title><content type='html'>&lt;span style=&quot;line-height: 19px;&quot;&gt;&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;A liposome formulator should pay a very close attention to the osmolality of the solution that is encapsulated inside the liposomes, the osmolality of the buffer outside of the liposomes and the osmolality of the medium that is used for in vitro studies.&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;line-height: 19px;&quot;&gt;&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;
&lt;div style=&quot;line-height: 19px;&quot;&gt;
&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;Liposome can be&amp;nbsp;osmotically&amp;nbsp;active or osmotically inactive. &amp;nbsp;In osmotically active liposomes the lipid membrane is permeable and the osmosis will occur. This is not the case when liposomes are not osmotically active.&amp;nbsp;&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;
&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif; line-height: 19px;&quot;&gt;The osmotic&amp;nbsp;behavior&amp;nbsp;of liposomes depend on their size, lamellarity and lipid composition.&amp;nbsp;&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif; line-height: 19px;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;br /&gt;
&lt;div style=&quot;line-height: 19px;&quot;&gt;
&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;Large unilamellar liposomes are osmotically active and therefore the osmolality of the solution that is encapsulated inside the large unilamellar liposomes should be equal to the buffer that is outside of the liposomes. If the liposomes are added to a medium for in vitro studies then the osmolality of the liposome solution should match the osmolality of the medium. If the liposomes are used for in vivo studies then the osmolality of liposomes should match the osmolality of blood.&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div style=&quot;line-height: 19px;&quot;&gt;
&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;Small unilamellar liposomes are NOT active osmotically and therefore there is not need to have iso-osmatic solutions inside and outside of liposomes.&amp;nbsp;&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div style=&quot;line-height: 19px;&quot;&gt;
&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;Multilamellar phosphatidylcholine based liposomes that contain a small amount of charged lipids are osmotically active.&amp;nbsp;Multilamellar phosphatidylcholine based liposomes that do not contain charged lipids are &amp;nbsp;NOT osmotically active.&amp;nbsp;&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div style=&quot;line-height: 19px;&quot;&gt;
&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;Very large oligolamellar liposomes with or without charged lipids are osmotically active.&lt;/span&gt;&lt;/div&gt;
&lt;div style=&quot;line-height: 19px;&quot;&gt;
&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;Many liposome based fluorescent assays used 100 nm liposomes. Most of the liposome based injectable drugs are 100 nm in size. These are LUVs and therefore they are osmotically &lt;/span&gt;&lt;u style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;active&lt;/u&gt;&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;.&amp;nbsp;&lt;/span&gt;&lt;/div&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/9084811576065914289'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/9084811576065914289'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2012/05/liposomes-and-osmolality-of-solution.html' title='Liposomes and osmolality of the solution'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-3066377766700486681</id><published>2012-05-27T09:48:00.002-05:00</published><updated>2012-05-27T09:50:01.647-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodrosome"/><category scheme="http://www.blogger.com/atom/ns#" term="Macrophage depletion"/><title type='text'>Package insert/injection instruction sheet for Clodronate liposomes: Clodrosome</title><content type='html'>&lt;div id=&quot;__ss_12984396&quot; style=&quot;width: 477px;&quot;&gt;
&lt;strong style=&quot;display: block; margin: 12px 0 4px;&quot;&gt;&lt;a href=&quot;http://www.slideshare.net/liposome/clodrosome-package-insert-encapsula-nano-sciences2012&quot; target=&quot;_blank&quot; title=&quot;Clodrosome-Clodronate Encapsulated Liposomes_ Package Insert Encapsula Nanosciences_2012&quot;&gt;Clodrosome-Clodronate Encapsulated Liposomes_ Package Insert Encapsula Nanosciences_2012&lt;/a&gt;&lt;/strong&gt; &lt;iframe allowfullscreen=&quot;&quot; frameborder=&quot;0&quot; height=&quot;510&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://www.slideshare.net/slideshow/embed_code/12984396?rel=0&quot; width=&quot;477&quot;&gt;&lt;/iframe&gt; &lt;br /&gt;
&lt;div style=&quot;padding: 5px 0 12px;&quot;&gt;
View more documents from &lt;a href=&quot;http://www.slideshare.net/liposome&quot; target=&quot;_blank&quot;&gt;Encapsula NanoSciences&lt;/a&gt; &lt;br /&gt;
&lt;br /&gt;
For more info go to &lt;a href=&quot;http://www.clodrosome.com/&quot;&gt;www.clodrosome.com&lt;/a&gt;&lt;/div&gt;
&lt;/div&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/3066377766700486681'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/3066377766700486681'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2012/05/package-insertinjection-instruction.html' title='Package insert/injection instruction sheet for Clodronate liposomes: Clodrosome'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-7284489304357683312</id><published>2012-05-27T09:47:00.000-05:00</published><updated>2012-05-27T09:50:12.858-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodrosome"/><category scheme="http://www.blogger.com/atom/ns#" term="Macrophage depletion"/><category scheme="http://www.blogger.com/atom/ns#" term="MSDS"/><title type='text'>MSDS for Plain liposomes-Clodronate liposome Control: Encapsome-CL</title><content type='html'>&lt;div id=&quot;__ss_12984857&quot; style=&quot;width: 477px;&quot;&gt;
&lt;strong style=&quot;display: block; margin: 12px 0 4px;&quot;&gt;&lt;a href=&quot;http://www.slideshare.net/liposome/msds-encapsome-clclodronate-liposome-controlencapsula-nanosciences2012&quot; target=&quot;_blank&quot; title=&quot;MSDS Encapsome CL_Clodronate Liposome Control-Encapsula NanoSciences_2012&quot;&gt;MSDS Encapsome CL_Clodronate Liposome Control-Encapsula NanoSciences_2012&lt;/a&gt;&lt;/strong&gt; &lt;iframe allowfullscreen=&quot;&quot; frameborder=&quot;0&quot; height=&quot;510&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://www.slideshare.net/slideshow/embed_code/12984857?rel=0&quot; width=&quot;477&quot;&gt;&lt;/iframe&gt; &lt;br /&gt;
&lt;div style=&quot;padding: 5px 0 12px;&quot;&gt;
View more documents from &lt;a href=&quot;http://www.slideshare.net/liposome&quot; target=&quot;_blank&quot;&gt;Encapsula NanoSciences&lt;/a&gt; &lt;br /&gt;
For more info go to&amp;nbsp;&lt;a href=&quot;http://www.clodrosome.com/&quot;&gt;www.clodrosome.com&lt;/a&gt;
&lt;/div&gt;
&lt;/div&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/7284489304357683312'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/7284489304357683312'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2012/05/msds-for-plain-liposomes-clodronate.html' title='MSDS for Plain liposomes-Clodronate liposome Control: Encapsome-CL'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-4863462194217209344</id><published>2012-05-27T09:45:00.000-05:00</published><updated>2020-01-24T16:26:35.713-06:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodronate liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Clodrosome"/><category scheme="http://www.blogger.com/atom/ns#" term="Macrophage depletion"/><category scheme="http://www.blogger.com/atom/ns#" term="MSDS"/><title type='text'>SDS for Clodronate liposomes: Clodrosome®</title><content type='html'>For more information about the product and macrophage depletion visit the link below:&lt;br /&gt;
&lt;div&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
&lt;a href=&quot;https://encapsula.com/products/macrophage-depletion-reagents-clodrosome/standard-reagents/standard-reagents-standard-reagents/clodrosome/&quot;&gt;https://encapsula.com/products/macrophage-depletion-reagents-clodrosome/standard-reagents/standard-reagents-standard-reagents/clodrosome/&lt;/a&gt;&lt;/div&gt;
&lt;div&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
Click here to have access to macrophage depletion products catalog:&lt;/div&gt;
&lt;div&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
&lt;a href=&quot;https://encapsula.com/product-category/macrophage-depletion-reagents-clodrosome/&quot;&gt;https://encapsula.com/product-category/macrophage-depletion-reagents-clodrosome/&lt;/a&gt;&lt;/div&gt;
&lt;div&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;b&gt;&lt;/b&gt;&lt;iframe allowfullscreen=&quot;&quot; frameborder=&quot;0&quot; height=&quot;714&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;//www.slideshare.net/slideshow/embed_code/key/3icJUI8dh6443n&quot; style=&quot;border-width: 1px; border: 1px solid #ccc; margin-bottom: 5px; max-width: 100%;&quot; width=&quot;668&quot;&gt; &lt;/iframe&gt;&lt;br /&gt;
&lt;div style=&quot;margin-bottom: 5px;&quot;&gt;
&lt;strong&gt; &lt;a href=&quot;https://www.slideshare.net/liposome/sds-for-clodrosome-by-encapsula-nanosciences&quot; target=&quot;_blank&quot; title=&quot;SDS for Clodrosome® by Encapsula NanoSciences&quot;&gt;SDS for Clodrosome® by Encapsula NanoSciences&lt;/a&gt; &lt;/strong&gt; from &lt;strong&gt;&lt;a href=&quot;https://www.slideshare.net/liposome&quot; target=&quot;_blank&quot;&gt;Encapsula NanoSciences&lt;/a&gt;&lt;/strong&gt; &lt;/div&gt;
</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/4863462194217209344'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/4863462194217209344'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2012/05/msds-for-clodronate-liposomes.html' title='SDS for Clodronate liposomes: Clodrosome®'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-3763560919239098834</id><published>2012-05-17T14:42:00.000-05:00</published><updated>2012-05-17T14:45:09.649-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Fluorescent liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="Fluoroliposome"/><category scheme="http://www.blogger.com/atom/ns#" term="fusion assay"/><category scheme="http://www.blogger.com/atom/ns#" term="Lipid movement in liposome bilayer"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="NBD/Rhodamine assay"/><title type='text'>Fluorescent Liposomes: Inner Monolayer Mixing Assay</title><content type='html'>&lt;table align=&quot;center&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; class=&quot;tr-caption-container&quot; style=&quot;margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;tbody&gt;
&lt;tr&gt;&lt;td style=&quot;text-align: center;&quot;&gt;&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj_3gnID0VrkoL9hPM9NiKYVqftCqr2mhk2ylxlz4ctUiBf5oHDNOK673q6-5bJ1CeLLNv6UmlEFx9xNZojo24-tAM7DgurATqszdlxxHE0ni3lvAbPmRgFdPH0S144Y49AzvYX_c1kGpA/s1600/NBD-RhoPE-Inner-Leaflet-Fusion-Assay.png&quot; imageanchor=&quot;1&quot; style=&quot;background-color: white; margin-left: auto; margin-right: auto;&quot;&gt;&lt;img border=&quot;0&quot; height=&quot;148&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj_3gnID0VrkoL9hPM9NiKYVqftCqr2mhk2ylxlz4ctUiBf5oHDNOK673q6-5bJ1CeLLNv6UmlEFx9xNZojo24-tAM7DgurATqszdlxxHE0ni3lvAbPmRgFdPH0S144Y49AzvYX_c1kGpA/s320/NBD-RhoPE-Inner-Leaflet-Fusion-Assay.png&quot; width=&quot;320&quot; /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;tr-caption&quot; style=&quot;text-align: center;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;Click on the image to enlarge it.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
&lt;br /&gt;
&lt;div style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; font-family: Arial; font-size: 13px; line-height: 22px; margin-bottom: 5px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 5px; padding-left: 0px; padding-right: 0px; padding-top: 5px; text-align: justify; vertical-align: baseline;&quot;&gt;
&lt;span style=&quot;background-color: white;&quot;&gt;&lt;span style=&quot;color: #333333;&quot;&gt;One of the main problems of using a lipid that has the fluorescence probe on the head group is that it can interact with fusogens, proteins and ions and this interaction may alter the&amp;nbsp;fluorescence&amp;nbsp;intensity or the lateral diffusion of the probe (See this&amp;nbsp;&lt;/span&gt;&lt;a href=&quot;http://www.liposomes.org/2011/10/lipid-movements-in-liposome.html&quot; style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #76820d; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-decoration: none; vertical-align: baseline;&quot; target=&quot;_blank&quot; title=&quot;Lipid movement in liposomes&quot;&gt;animation&lt;/a&gt;&lt;span style=&quot;color: #333333;&quot;&gt;&amp;nbsp;which explains various movements of lipids in liposome bilayer). &amp;nbsp;If the fluorophores are only located in the inner monolayer of the liposomes then the fluorescence would no be affected by ions, proteins, peptides and other fusogens that bind to the surface of the liposomes. The fluorophores &amp;nbsp;that are exposed to the outer monolayer can be reduced using dithionate and therefore eliminating the fluorescence of the outer monolayer. NBD-phosphatidylserine (NBD-PS) is is more suitable to be used for these formulations than NBD-phosphatidylethanolamine (NBD-PE) because PS is less prone to transbilayer movement following reduction by&amp;nbsp;dithionate. This method was originally developed by The Liposome Company (Princeton, NJ) in 1999. See here:&lt;/span&gt;&lt;span style=&quot;color: blue;&quot;&gt;&amp;nbsp;&lt;a href=&quot;http://dx.doi.org/10.1016/S0005-2736(00)00224-8&quot; style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-decoration: none; vertical-align: baseline;&quot; target=&quot;_blank&quot; title=&quot;Novel inner monolayer fusion assays reveal differential monolayer mixing associated with cation-dependent membrane fusion&quot;&gt;Novel inner monolayer fusion assays reveal differential monolayer mixing associated with cation-dependent membrane fusion&lt;/a&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;h4 style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #333333; font-family: Arial; font-size: 1.333em !important; line-height: 1.2em; margin-bottom: 2px; margin-left: 0px; margin-right: 0px; margin-top: 15px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 2px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: left; vertical-align: baseline;&quot;&gt;

&lt;span style=&quot;background-color: white;&quot;&gt;Reduction of Outer Exposed Fluorphores/Inner Monolayer Mixing Assay&lt;/span&gt;&lt;/h4&gt;
&lt;ol style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #333333; font-family: Arial; font-size: 13px; line-height: 22px; list-style-image: initial; list-style-position: initial; margin-bottom: 2px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: justify; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;Liposomes containing 0.8 mole% of NBD-PS and 0.8 mole% Rhodamine-PE with total lipid concentration of 20 mM is prepared (Concentrated stock solution of labeled fluorescent&amp;nbsp;liposomes)&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;Liposomes containing 0.08 mole% of NBD-PS and 0.08 mole% Rhodamine-PE&amp;nbsp;with total lipid concentration of 20 mM is prepared (Concentrated stock solution of mock-fused liposomes)&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;Dithionate is added at a final concentration of 100 mM to 10 mM solution of labeled fluorescent liposomes and the solution is incubated for 1 hour at 4 C in refrigerator.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;Dithionate is added at a final concentration of 100 mM to 10 mM solution of mock-fused liposomes&amp;nbsp;and the solution is incubated for 1 hour at 4 C in refrigerator.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;Dithonate is removed by either dialysis or spin column.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;In order to perform fusion assay three batches of liposomes are needed: a) Inner monolayer labeled fluorescent&amp;nbsp;liposomes (Containing 0.8 mol% of labeled&amp;nbsp;lipid)&amp;nbsp;b) Plain unlabeled liposomes c) &amp;nbsp;Inner monolayer labeled mock-fused liposomes&amp;nbsp;(Containing 0.08 mol% of labeled&amp;nbsp;lipid).&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;On fluorometer set the excitation monochromator to 460 nm and emission monochromator to 535 nm.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;For a fusion assay that&amp;nbsp;utilizes 50 µM&amp;nbsp;total lipid,&amp;nbsp;take the appropriate amount of labeled &amp;nbsp;liposomes and add it to the buffer inside the fluorometer cuvette to make a 5 µM of labeled fluorescent&amp;nbsp;liposomes and also&amp;nbsp;&amp;nbsp;take the appropriate amount of plain liposomes and add it to the buffer inside the fluorometer cuvette to make a 45&amp;nbsp;µM of plain liposomes. The total lipid concentration will be 50&amp;nbsp;µM. The labeled and plain liposomes are mixed at 10:90 molar ratio.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;Measure the fluorescence of the solution and adjust it to an&amp;nbsp;arbitrary&amp;nbsp;unit of 0%.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;Take the appropriate amount of Mock-fused liposomes&amp;nbsp;and add it to the buffer inside the fluorometer cuvette to make a liposome solution with total lipid concentration of 50 µM.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;Measure the fluorescence of the solution and adjust it to an&amp;nbsp;arbitrary&amp;nbsp;unit of 100%. &amp;nbsp;Mock-fused&amp;nbsp;liposomes&amp;nbsp;represent the theoretical fusion product.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;The percentage of lipid mixing as a function of time is calculated using the following equation,&amp;nbsp;where M(t) is the extent of lipid inter-mixing at time t, I (t) is the fluorescence intensity at time t, I(0) is the fluorescence intensity of the initial mixture of labeled liposome and plain liposomes (step 3 and 4). I(∞) is the fluorescence&amp;nbsp;intensity&amp;nbsp;of Mock-fused liposomes&amp;nbsp;(steps 5 and 6).&lt;/span&gt;&lt;/li&gt;
&lt;/ol&gt;
&lt;div style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #333333; font-family: Arial; font-size: 13px; line-height: 22px; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: justify; vertical-align: baseline;&quot;&gt;
&lt;/div&gt;
&lt;div style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #333333; font-family: Arial; font-size: 13px; line-height: 22px; margin-bottom: 5px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 5px; padding-left: 210px; padding-right: 0px; padding-top: 5px; text-align: justify; vertical-align: baseline;&quot;&gt;
&lt;a href=&quot;http://www.fluoroliposome.com/wp-content/uploads/2012/04/Lipid-Intermixing-equation1.jpg&quot; rel=&quot;wp-prettyPhoto[90]&quot; style=&quot;background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #76820d; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-decoration: none; vertical-align: baseline;&quot;&gt;&lt;img alt=&quot;&quot; height=&quot;49&quot; src=&quot;http://www.fluoroliposome.com/wp-content/uploads/2012/04/Lipid-Intermixing-equation1.jpg&quot; style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot; title=&quot;Lipid  Intermixing equation&quot; width=&quot;200&quot; /&gt;&lt;/a&gt;&lt;/div&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/3763560919239098834'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/3763560919239098834'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2012/05/fluorescent-liposomes-inner-monolayer.html' title='Fluorescent Liposomes: Inner Monolayer Mixing Assay'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj_3gnID0VrkoL9hPM9NiKYVqftCqr2mhk2ylxlz4ctUiBf5oHDNOK673q6-5bJ1CeLLNv6UmlEFx9xNZojo24-tAM7DgurATqszdlxxHE0ni3lvAbPmRgFdPH0S144Y49AzvYX_c1kGpA/s72-c/NBD-RhoPE-Inner-Leaflet-Fusion-Assay.png" height="72" width="72"/></entry><entry><id>tag:blogger.com,1999:blog-4184396470845122639.post-1649969618130138776</id><published>2012-05-17T13:43:00.000-05:00</published><updated>2012-05-17T15:24:52.743-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Fluorescent liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="fusion assay"/><category scheme="http://www.blogger.com/atom/ns#" term="Lipid movement in liposome bilayer"/><category scheme="http://www.blogger.com/atom/ns#" term="Liposomes"/><category scheme="http://www.blogger.com/atom/ns#" term="NBD/Rhodamine assay"/><title type='text'>Fluorescent Liposomes: Intermixing of lipids during liposome fusion (NBD/Rhodamine Assay)</title><content type='html'>&lt;table align=&quot;center&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; class=&quot;tr-caption-container&quot; style=&quot;margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;tbody&gt;
&lt;tr&gt;&lt;td style=&quot;text-align: center;&quot;&gt;&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg7Sg5v1i6OWFCnBnO2aTqBdYBbHng8ETV0lwweCKkw8gJKTNtUuzBq4uM_B5_-TzQbmrTJTCDJD_nWeoZfKjpqxvkiZ1a9PqQf1sqgTmLa5YNZ8q4zLPq2OjQUGLErpQRMKmnn8T4YPGY/s1600/NBD-RhoPE-Fusion-Assay.png&quot; imageanchor=&quot;1&quot; style=&quot;margin-left: auto; margin-right: auto;&quot;&gt;&lt;img border=&quot;0&quot; height=&quot;148&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg7Sg5v1i6OWFCnBnO2aTqBdYBbHng8ETV0lwweCKkw8gJKTNtUuzBq4uM_B5_-TzQbmrTJTCDJD_nWeoZfKjpqxvkiZ1a9PqQf1sqgTmLa5YNZ8q4zLPq2OjQUGLErpQRMKmnn8T4YPGY/s320/NBD-RhoPE-Fusion-Assay.png&quot; width=&quot;320&quot; /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;tr-caption&quot; style=&quot;text-align: center;&quot;&gt;Click on the picture to enlarge it.&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
&lt;ol style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #333333; font-family: Arial; font-size: 13px; line-height: 22px; list-style-image: initial; list-style-position: initial; margin-bottom: 2px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: justify; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;In order to perform fusion assay three batches of liposomes are needed: a) Labeled fluorescent&amp;nbsp;liposomes (Containing 0.8 mol% of Rhodamine labeled lipid AND 0.8 mol% NBD labeled lipid- Please notice that BOTH labeled lipids should be present in the same liposomes&amp;nbsp;)&amp;nbsp;b) Plain unlabeled liposomes c) &amp;nbsp;Mock-fused liposomes&amp;nbsp;(Containing 0.08 mol% of&amp;nbsp;Rhodamine labeled lipid AND 0.08 mol% NBD labeled lipid).&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;On fluorometer set the excitation monochromator to 460 nm and emission monochromator to 535 nm.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;For a fusion assay that&amp;nbsp;utilizes 50 µM&amp;nbsp;total lipid,&amp;nbsp;take the appropriate amount of labeled &amp;nbsp;liposomes and add it to the buffer inside the fluorometer cuvette to make a 5 µM of labeled fluorescent&amp;nbsp;liposomes and also&amp;nbsp;&amp;nbsp;take the appropriate amount of plain liposomes and add it to the buffer inside the fluorometer cuvette to make a 45&amp;nbsp;µM of plain liposomes. The total lipid concentration will be 50&amp;nbsp;µM. The labeled and plain liposomes are mixed at 10:90 molar ratio.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;Measure the fluorescence of the solution and adjust it to an&amp;nbsp;arbitrary&amp;nbsp;unit of 0%.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;Take the appropriate amount of Mock-fused liposomes&amp;nbsp;and add it to the buffer inside the fluorometer cuvette to make a liposome solution with total lipid concentration of 50 µM.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;Measure the fluorescence of the solution and adjust it to an&amp;nbsp;arbitrary&amp;nbsp;unit of 100%. &amp;nbsp;Mock-fused&amp;nbsp;liposomes&amp;nbsp;represent the theoretical fusion product.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;The percentage of lipid mixing as a function of time is calculated using the following equation,&amp;nbsp;where M(t) is the extent of lipid inter-mixing at time t, I (t) is the fluorescence intensity at time t, I(0) is the fluorescence intensity of the initial mixture of labeled liposome and plain liposomes (step 3 and 4). I(∞) is the fluorescence&amp;nbsp;intensity&amp;nbsp;of Mock-fused liposomes&amp;nbsp;(steps 5 and 6).&lt;/span&gt;&lt;/li&gt;
&lt;/ol&gt;
&lt;div style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #333333; font-family: Arial; font-size: 13px; line-height: 22px; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: justify; vertical-align: baseline;&quot;&gt;
&lt;/div&gt;
&lt;div style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #333333; font-family: Arial; font-size: 13px; line-height: 22px; margin-bottom: 5px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 5px; padding-left: 0px; padding-right: 0px; padding-top: 5px; text-align: justify; vertical-align: baseline;&quot;&gt;
&lt;a href=&quot;http://www.fluoroliposome.com/wp-content/uploads/2012/04/Lipid-Intermixing-equation1.jpg&quot; rel=&quot;wp-prettyPhoto[90]&quot; style=&quot;background-attachment: initial; background-clip: initial; background-color: white; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #76820d; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-decoration: none; vertical-align: baseline;&quot;&gt;&lt;img alt=&quot;&quot; class=&quot;aligncenter size-full wp-image-208&quot; height=&quot;67&quot; src=&quot;http://www.fluoroliposome.com/wp-content/uploads/2012/04/Lipid-Intermixing-equation1.jpg&quot; style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; display: block; margin-bottom: 10px !important; margin-left: auto !important; margin-right: auto !important; margin-top: 6px !important; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot; title=&quot;Lipid  Intermixing equation&quot; width=&quot;270&quot; /&gt;&lt;/a&gt;&lt;/div&gt;
&lt;h4 style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #333333; font-family: Arial; font-size: 1.333em !important; line-height: 1.2em; margin-bottom: 2px; margin-left: 0px; margin-right: 0px; margin-top: 15px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 2px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: justify; vertical-align: baseline;&quot;&gt;





&lt;span style=&quot;background-color: white;&quot;&gt;Notes:&lt;/span&gt;&lt;/h4&gt;
&lt;ol style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; font-family: Arial; font-size: 13px; line-height: 22px; list-style-image: initial; list-style-position: initial; margin-bottom: 2px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;&quot;&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; color: #333333; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: justify; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;In many papers, the maximal fluorescence was determined by lysing the&amp;nbsp;labeled&amp;nbsp;liposomes&amp;nbsp;at the concentration to be used in the assay. The lysing is done by using a detergent. We have used “mock-fused liposomes” for measuring the maximal fluorescence. The reason is that using detergents can add a&amp;nbsp;substantial&amp;nbsp;error. As an example Triton X-100 has inhibitory effect on the fluorescence of NBD and affects the quantum yield of NBD. If Triton X-100 is used a correction factor of 1.4-1.5 should be used. Instead of Triton X-100, alternative detergents such as C&lt;sub&gt;12&lt;/sub&gt;E&lt;sub&gt;8&lt;/sub&gt;&amp;nbsp;adn C&lt;sub&gt;12&lt;/sub&gt;E&lt;sub&gt;9&amp;nbsp;&lt;/sub&gt;are recommended to be used.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 30px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: justify; vertical-align: baseline;&quot;&gt;&lt;span style=&quot;background-color: white;&quot;&gt;&lt;span style=&quot;color: #333333;&quot;&gt;One of the main problems of using a lipid that has the fluorescence probe on the head group is that it can interact with fusogens, proteins and ions and this interaction may alter the&amp;nbsp;fluorescence&amp;nbsp;intensity or the lateral diffusion of the probe (See this&amp;nbsp;&lt;/span&gt;&lt;a href=&quot;http://www.liposomes.org/2011/10/lipid-movements-in-liposome.html&quot; style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-decoration: none; vertical-align: baseline;&quot; target=&quot;_blank&quot; title=&quot;Lipid movement in liposomes&quot;&gt;&lt;span style=&quot;color: blue;&quot;&gt;animation&lt;/span&gt;&lt;/a&gt;&lt;span style=&quot;color: #333333;&quot;&gt;&amp;nbsp;which explains various movements of lipids in liposome bilayer). &amp;nbsp;If the fluorophores are only located in the inner monolayer of the liposomes then the fluorescence would no be affected by ions, proteins, peptides and other fusogens that bind to the surface of the liposomes. The fluorophores &amp;nbsp;that are exposed to the outer monolayer can be reduced using dithionate and therefore eliminating the fluorescence of the outer monolayer. NBD-phosphatidylserine (NBD-PS) is is more suitable to be used for these formulations than NBD-phosphatidylethanolamine (NBD-PE) because PS is less prone to transbilayer movement following reduction by&amp;nbsp;dithionate. This method was originally developed by The Liposome Company (Princeton, NJ) in 1999.&amp;nbsp;&lt;/span&gt;&lt;/span&gt;
&lt;span style=&quot;background-color: white;&quot;&gt;&lt;span style=&quot;color: #333333;&quot;&gt;See here:&amp;nbsp;&lt;/span&gt;&lt;a href=&quot;http://dx.doi.org/10.1016/S0005-2736(00)00224-8&quot; style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-decoration: none; vertical-align: baseline;&quot; target=&quot;_blank&quot; title=&quot;Novel inner monolayer fusion assays reveal differential monolayer mixing associated with cation-dependent membrane fusion&quot;&gt;&lt;span style=&quot;color: blue;&quot;&gt;Novel inner monolayer fusion assays reveal differential monolayer mixing associated with cation-dependent membrane fusion&lt;/span&gt;&lt;/a&gt;&lt;span style=&quot;color: #333333;&quot;&gt;. To see a step by step instruction of this assay see here:&amp;nbsp;&lt;/span&gt;&lt;a href=&quot;http://www.liposomes.org/2012/05/fluorescent-liposomes-inner-monolayer.html&quot; style=&quot;background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-image: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-decoration: none; vertical-align: baseline;&quot; target=&quot;_blank&quot; title=&quot;Inner Monolayer Mixing Assay&quot;&gt;&lt;span style=&quot;color: blue;&quot;&gt;Inner Monolayer Mixing Assay&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;
&lt;/ol&gt;</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/1649969618130138776'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4184396470845122639/posts/default/1649969618130138776'/><link rel='alternate' type='text/html' href='http://www.liposomes.org/2012/05/intermixing-of-lipids-during-liposome.html' title='Fluorescent Liposomes: Intermixing of lipids during liposome fusion (NBD/Rhodamine Assay)'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg7Sg5v1i6OWFCnBnO2aTqBdYBbHng8ETV0lwweCKkw8gJKTNtUuzBq4uM_B5_-TzQbmrTJTCDJD_nWeoZfKjpqxvkiZ1a9PqQf1sqgTmLa5YNZ8q4zLPq2OjQUGLErpQRMKmnn8T4YPGY/s72-c/NBD-RhoPE-Fusion-Assay.png" height="72" width="72"/></entry></feed>